Compositions and methods for genome modification of cells and uses thereof

JP2023548478A5Active Publication Date: 2024-11-05ARSENAL BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526200
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-29
Filing Date
2021-10-29
Publication Date
2024-11-05
Estimated Expiration
2041-10-29

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are compositions and methods for producing genome-edited cells that express an exogenous transgene and restore or continue expression of an endogenous gene. Also provided are methods of using the genome-edited cells to treat or prevent disease in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to Related Applications This application claims the benefit and priority of U.S. Provisional Patent Application No. 63 / 107,401, filed on October 29, 2020, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0002] Sequence Listing This application is electronically filed in ASCII format and includes a sequence listing that is incorporated herein by reference in its entirety as part of this specification. The ASCII copy created on October 29, 2021 has the name ANB - 204WO SL ST25.txt and a size of 368,991 bytes.

[0003] Field of the Invention The present invention generally relates to compositions and methods for the insertion of transgenes into cells, which are applicable to adoptive cell therapy.

Background Art

[0004] Background Genetically engineered immunotherapy has been developed over several decades and has been proven effective in the treatment of certain cancers. The evolution from random integration of viral gene - modification methods to targeted non - viral integration is expected to greatly unlock the potential of cell immunotherapy. However, important engineering challenges specific to targeted transgene integration remain. The efficiency of transgene integration is always less than 100%, and current methods for selecting and / or enriching cells into which the transgene has been integrated are largely based on the expression of transgene products that enable affinity purification or confer antibiotic resistance.

[0005] For example, a transgene can be engineered to include a gene encoding a cell surface protein exposed to an antibody reagent, which can then be fluorescently labeled to enable fluorescence-activated cell classification (FACS) or bound to magnetic beads to allow magnetic-based enrichment. Alternatively, cells can be engineered to express a fluorescent protein (e.g., green fluorescent protein) to enable FACS. In another example, an antibiotic resistance marker (e.g., a puromycin resistance gene) can be incorporated into the transgene and expressed from that transgene. This allows cells with successful transgene integration to be antibiotic-resistant, while cells with unsuccessful integration may become sensitive to antibiotic treatment. While these standard methods are effective, if the protein is a cell surface protein, the expression of the foreign protein needs to be relatively long unless a selective reagent for the transgene itself can be created.

[0006] In an alternative approach, the transgene can be incorporated into a gene locus such as hypoxanthine phosphoribosyltransferase (HPRT). HPRT catalyzes the conversion of 2-thioguanine to a cytotoxic metabolite. Insertion of the transgene into the HPRT locus disrupts HPRT expression, and the cells into which the transgene is incorporated can be selected by treating the cells with 2-thioguanine. This method and other methods of site-specific transgene insertion are often performed on genes essential for the survival or function of host cells, and the insertion usually inactivates the gene at the insertion site. Therefore, a method that simultaneously achieves transgene insertion while modifying gene disruption to promote cell survival and function is beneficial for the development and application of adoptive immunotherapy. [Overview of the Initiative]

[0007] This disclosure relates to compositions and methods for inserting site-directed transgenes into the genome of cells while maintaining the expression of locus products that benefit cell health and survival.

[0008] This specification provides compositions for targeted insertion of nucleic acids, comprising a sequence having coding ability equivalent to the 3' portion of an endogenous gene within a cell and an exogenous transgene. In some embodiments, the composition is Guide RNA (gRNA) that targets endogenous genes; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid comprising a sequence that forms a complex with an RNA-inducible nuclease and encodes one or more regions homologous to an endogenous gene, a sequence having coding ability equivalent to the 3' portion of the endogenous gene, and a transgene. This includes the following: In some embodiments, the RNA-inducible nuclease specifically cleaves an endogenous gene in the cell to create an insertion site, and a sequence of nucleic acid having coding ability equivalent to the 3' portion of the endogenous gene and the introduced gene are inserted into the insertion site, and the insertion of the sequence of nucleic acid having coding ability equivalent to the 3' portion of the endogenous gene and the introduced gene results in the restoration or continuation of the expression of the endogenous gene and the expression of the introduced gene in the cell.

[0009] In another embodiment, the composition is Guide gRNAs that target endogenous genes; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid comprising a sequence that forms a complex with an RNA-inducible nuclease and encodes one or more regions homologous to an endogenous gene, an exogenous transgene, and a sequence having coding ability equivalent to the 5' portion of the endogenous gene. This includes the following: In some embodiments, the RNA-inducible nuclease specifically cleaves an endogenous gene within a cell to create an insertion site, into which a sequence of nucleic acid having coding ability equivalent to the 5' portion of the introduced gene and the endogenous gene is inserted, and the insertion of the nucleic acid with the sequence having coding ability equivalent to the 5' portion of the introduced gene and the endogenous gene results in the restoration or continuation of the expression of the endogenous gene and the expression of the introduced gene in the cell.

[0010] Furthermore, this specification provides a cell comprising nucleic acid having, in its 5' to 3' region, (1) a sequence encoding the 5' portion of the cell's endogenous gene, (2) a sequence having coding ability equivalent to the 3' portion of the cell's endogenous gene, (3) a sequence encoding an exogenous transgene, and (4) a sequence encoding the 3' portion of the cell's endogenous gene, wherein the cell expresses the endogenous gene encoded by (1) and (2) and the transgene encoded by (3).

[0011] In another embodiment, the Specified provides a cell comprising nucleic acid having, in its 5' to 3' region, (1) a sequence having coding ability equivalent to the 5' portion of the cell's endogenous gene, (2) a sequence encoding an exogenous transgene, (3) a sequence encoding the 5' portion of the cell's endogenous gene, and (4) a sequence encoding the 3' portion of the cell's endogenous gene, wherein the cell expresses the transgene encoded by (2) and the endogenous genes encoded by (3) and (4).

[0012] In another embodiment, this specification provides a method for editing the genome of a cell, gRNAs that target endogenous genes; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid comprising a sequence that forms a complex with an RNA-inducible nuclease and encodes one or more regions homologous to an endogenous gene, a sequence having coding ability equivalent to the 3' portion of the endogenous gene, and an exogenous transgene. The present invention provides a method comprising introducing into cells. In some embodiments, the RNA-inducible nuclease specifically cleaves an endogenous gene in the cell to create an insertion site, and a sequence of nucleic acid having coding ability equivalent to the 3' portion of the endogenous gene and the exogenous transgene are inserted into the insertion site, and the insertion of the sequence of nucleic acid having coding ability equivalent to the 3' portion of the endogenous gene and the exogenous transgene results in the restoration or continuation of the expression of the endogenous gene and the expression of the transgene in the cell.

[0013] In yet another embodiment, this specification provides a method for editing the genome of a cell, gRNAs that target endogenous genes; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid comprising a sequence that forms a complex with an RNA-inducible nuclease and encodes one or more regions homologous to an endogenous gene, an exogenous transgene, and a sequence having coding ability equivalent to the 5' portion of the endogenous gene. The present invention provides a method comprising introducing into cells. In some embodiments, the RNA-inducible nuclease specifically cleaves an endogenous gene in the cell to create an insertion site, and a sequence of nucleic acid having coding ability equivalent to the 5' portion of the exogenous transgene and the endogenous gene is inserted into the insertion site, and the insertion of the nucleic acid with the sequence having coding ability equivalent to the 5' portion of the exogenous transgene and the endogenous gene results in the restoration or continuation of the expression of the endogenous gene and the expression of the transgene in the cell.

[0014] In some embodiments, gRNA, RNA-inducible nucleases, and nucleic acids are introduced into cells via non-viral delivery. For example, in some embodiments, gRNA, RNA-inducible nucleases, and nucleic acids are introduced into cells via electroporation. In some embodiments, gRNA, RNA-inducible nucleases, and / or nucleic acids are introduced into cells via viral delivery. For example, in some embodiments, gRNA, RNA-inducible nucleases, and / or nucleic acids are introduced into cells via adeno-associated virus (e.g., AAV6).

[0015] In some embodiments, the endogenous gene is selected from the group consisting of the T cell receptor alpha chain constant region (TRAC), the T cell receptor beta chain constant region (TRBC), the CD3γ chain, the CD3δ chain, the CD3ε chain, the CD3ξ chain, the IL-2Rα chain, the IL-2Rβ chain, and the IL-2Rγ chain (IL2RG). For example, in some embodiments, the endogenous gene is TRAC. For example, in another embodiment, the endogenous gene is IL2RG.

[0016] In some embodiments, the endogenous genes are beta-actin (Actb) and ATP synthase H + The endogenous gene is one or more of the following: transport, mitochondrial F0 complex subunit B1 (Atp5f1), beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphoribosyltransferase (Hprt), phosphoglycerate kinase I (Pgk1), peptidyl prolyl isomerase A (Ppia), ribosomal protein S18 (Rps18), TATA box-binding protein (Tbp), transferrin receptor (Tfrc), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase-activating protein zetapolypeptide (Ywhaz), Nanog homeobox (Nanog), zinc finger protein 42 (Rex1), and POU domain class 5 transcription factor 1 (Oct4). In some embodiments, the endogenous gene is Gapdh.

[0017] In some embodiments, the transgene includes a chimeric antigen receptor (CAR).

[0018] In some embodiments, the cells are immune cells, and optionally T cells. For example, in some embodiments, the T cells are CD4+ or CD8+ T cells. In some embodiments, the cells are induced pluripotent stem cells (iPSCs). In some embodiments, the cells are iPSC-derived natural killer cells (iNKs). In some embodiments, the immune cells are immune cell progenitor cells, such as pluripotent stem cells.

[0019] In some embodiments, the RNA-induced nuclease is Cas9.

[0020] In some mechanisms, gRNA is either a single guide RNA (sgRNA) or a crRNA: transactivating RNA (tracrRNA).

[0021] In another embodiment, a method is provided for treating a disease in a subject, comprising obtaining cells containing nucleic acids as described herein, and administering the cells to the subject. In some embodiments, the disease is cancer. In some embodiments, the cells are obtained from the subject. For example, in certain embodiments, the cells are T cells, and optionally, CD4+ or CD8+ T cells. [Brief explanation of the drawing]

[0022] [Figure 1] This is a conceptual diagram illustrating the exemplary introduction of nucleic acids encoding guide RNA (gRNA), RNA-inducible nucleases (e.g., Cas9), and exogenous transgenes (e.g., chimeric antigen receptors (CARs)). Sequences with coding ability equivalent to the 5' or 3' portion of an endogenous gene in a cell (e.g., the T cell receptor alpha chain constant region (TRAC)) result in the expression of both the exogenous transgene and the endogenous gene.

[0023] [Figure 2A] This is a conceptual diagram illustrating the insertion of sequences with coding capabilities equivalent to the 3' portion of an endogenous gene and exogenous transgenes into double-strand breaks of endogenous genes within a cell, which have been cleaved by RNA-induced nucleases. [Figure 2B] This is a conceptual diagram illustrating exemplary results for T cell editing by nonviral targeting of IL2RG, both with and without gene circuit insertion.

[0024] [Figure 3]Figure 3 shows flow cytometry dot plots of T cells electroporated with CRISPR ribonucleoprotein (RNP) targeting the TRAC locus using a plasmid repair template. Figure 3A shows flow cytometry dot plots of T cells electroporated with plasmid repair templates encoding CRISPR RNP, as well as CAR and cleaved EGFR transgenes. Figure 3B shows flow cytometry dot plots of T cells electroporated with plasmid repair templates encoding CRISPR RNP, as well as CAR, cleaved EGFR transgenes, and all subsequent coding sequences of TRAC beyond the CRISPR target cleavage site. Figure 3C shows flow cytometry dot plots of EGFR-positive cells from B.

[0025] [Figure 4] This graph shows the multiplier of increase in the percentage of CAR-expressing cells in T cells that were electroporated with CRISPR RNPs targeting the TRAC gene locus using a plasmid repair template and stimulated with CD3 / CD28 beads.

[0026] [Figure 5] Flow cytometry dot plots of T cells obtained from two donors electroporated with CRISPR-ribonucleoprotein (RNP) targeting the IL2RG locus, which has a plasmid repair template that expresses an exogenous transgene encoding a circuit containing Prime and CAR receptors and a Myc tag, are shown at 9 and 14 days post-electroporation.

[0027] [Figure 6A] This graph shows the percentage of T cells expressing both IL2RG and the exogenous transgene on days 9 and 14 after electroporation, obtained from four donors electroporated with CRISPR-ribonucleoprotein (RNP) targeting the IL2RG locus, which has a plasmid repair template that expresses an exogenous transgene encoding a circuit containing Prime and CAR receptors and a Myc tag (pS6651).

[0028] [Figure 6B] This graph shows the percentage of T cells obtained from four donors electroporated with CRISPR-ribonucleoprotein (RNP) targeting the IL2RG locus, which has a plasmid repair template that expresses an exogenous transgene encoding a circuit containing Prime and CAR receptors and a Myc tag (pS6651). The percentage of cells in which IL2RG was knocked out and the transgene was not incorporated, on days 9 and 14 after electroporation. [Modes for carrying out the invention]

[0029] Detailed explanation The present invention provides a composition and method for targeted insertion of nucleic acids into target sites within endogenous genes within cells, wherein the nucleic acid comprises an exogenous transgene and a portion of an endogenous gene, and the insertion of the nucleic acid results in the expression of the exogenous transgene within the cell and restores or continues the expression of the endogenous gene. Restoring or continuing the expression of endogenous genes in cells is beneficial for cell health and survival and / or may be advantageous for the production of therapeutic cells.

[0030] To facilitate understanding of the present invention, numerous terms and phrases are defined below.

[0031] As used herein, the terms "a" and "an" mean "one or more" and include the plural form unless the context is appropriate.

[0032] The terms “nucleic acid,” “nucleotide,” or “oligonucleotide” refer to single-stranded or double-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and their polymers. Unless otherwise specified, the terms encompass nucleic acids including known analogues of native nucleotides that have similar binding properties to the reference nucleic acid and are metabolized in a similar manner to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence implicitly includes not only the explicitly stated sequence but also its conservatively modified variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences. Specifically, degenerate codon substitution can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced with a mixed base and / or a deoxyinosine residue (Batzer et al., Nucleic Acid Res. 19:5081 (1991), Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985), and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0033] The term "gene" may refer to a DNA fragment involved in the production or coding of polypeptide chains. The term "gene" may include the regions before and after the coding region (leaders and trailers) and the intervening sequences (introns) between individual coding fragments (exons). Alternatively, the term "gene" may refer to a DNA fragment involved in the production or coding of non-coding RNAs such as rRNA, tRNA, guide RNA (gRNA), short interfering RNA (siRNA), or microRNA (miRNA).

[0034] As used herein, the term “endogenous” with respect to nucleic acids, such as genes or proteins within a cell, refers to nucleic acids or proteins that arise within a particular cell as they would in nature, for example, at its natural genomic location or locus. Furthermore, a cell that “endogenously expresses” a nucleic acid or protein expresses that nucleic acid or protein as it would in nature.

[0035] A “promoter” is defined as one or more nucleic acid regulatory sequences that direct the transcription of a nucleic acid. As used herein, a “promoter” includes a nucleic acid sequence near the transcription start site, such as a TATA element, in the case of a polymerase II type promoter. Promoters also optionally include distal enhancer or repressor elements located at a distance of several thousand base pairs from the transcription start site.

[0036] Nucleic acids are "operably linked" when they are placed in a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operablely linked to a coding sequence if it affects the transcription of that sequence, or a ribosome binding site is operablely linked to a coding sequence if it is positioned to facilitate translation.

[0037] As used herein, the term “equivalent coding sequence” refers to a nucleic acid sequence that is functionally equivalent to another reference nucleic acid. An equivalent coding sequence may or may not have the same primary nucleotide sequence. For example, with respect to a reference nucleic acid encoding an expressed polypeptide, an equivalent coding sequence may be capable of functionally encoding the same expressed polypeptide and may contain the same primary nucleotide sequence as the reference nucleic acid, or it may contain one or more alternative codons compared to the reference nucleic acid. For example, an endogenous nucleic acid sequence encoding a polypeptide may be modified via codon optimization to produce a sequence encoding the same polypeptide. A codon-optimized sequence may be one in which codons in the polynucleotide encoding the polypeptide are substituted to alter the activity, expression, and / or stability of the polypeptide. For example, codon optimization can be used to change the degree of sequence similarity of an equivalent coding sequence to an endogenous gene sequence while retaining the ability of the endogenous gene to encode the protein product.

[0038] The terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to polymers of amino acid residues. As used herein, the above terms encompass amino acid chains of any length, including full-length proteins, in which amino acid residues are linked by covalent peptide bonds.

[0039] As used herein, the terms “complementary” or “complementarity” refer to specific base pairings between nucleotides or nucleic acids. Complementary nucleotides are generally A and T (or A and U), as well as G and C. Guide RNAs (gRNAs) described herein may include sequences, for example, DNA targeting sequences that are fully complementary or substantially complementary (e.g., having 1 to 4 mismatches) to a genomic sequence.

[0040] As used herein, the term “target-directed nuclease” refers to an endonuclease that recognizes and binds to a specific sequence of DNA and introduces a single-strand or double-strand break at a specific cleavage site. Target nucleases include, but are not limited to, RNA-induced nucleases, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), and megaTALs.

[0041] As used herein, the term “RNA-induced nuclease” refers to an endonuclease that can be used to perform targeted genome editing by forming a complex with a guide RNA (e.g., sgRNA or crRNA:tracrRNA).

[0042] As used herein, the term “target cleavage site” refers to a genomic site that an endoclease specifically cleaves, resulting in single-strand or double-strand breaks.

[0043] The "CRISPR / Cas" system refers to a broad class of bacterial systems for defense against foreign nucleic acids. CRISPR / Cas systems are found in a wide range of eubacteria and archaea. CRISPR / Cas systems include type I, type II, and type III subtypes. The wild-type type II CRISPR / Cas system utilizes RNA-inducible nucleases, such as Cas9, which form complexes with guide RNA and activating RNA, to recognize and cleave foreign nucleic acids. Guide RNAs possessing both guide RNA and activating RNA activity are also known in the art. In some cases, such dual-active guide RNAs are called single guide RNAs (sgRNAs).

[0044] Cas9 homologs are found in a wide range of bacteria, including, but not limited to, the following taxa: Actinobacteria, Aquificae, Bacteroidetes-Chlorobi, Chlamydiae-Verrucomicrobia, Chloroflexi, Cyanobacteria, Firmicutes, Proteobacteria, Spirochaetes, and Thermotogae. An exemplary Cas9 protein is the Cas9 protein of Streptococcus pyogenes. Further Cas9 proteins and their homologs are described, for example, in Chylinksi, et al., RNA Biol. 2013 May 1, 10(5):726-737, Nat. Rev. Microbiol. 2011 June, 9(6):467-477; Hou, et al., Proc Natl Acad Sci US A. 2013 Sep 24; 110(39):15644-9; Sampson et al., Nature. 2013 May 9; 497(7448):254-7, and Jinek, et al., Science. 2012 Aug 17; 337(6096):816-21. Any variant of the Cas9 nucleases provided herein can be optimized for efficient enhancement of activity or stability in host cells. Thus, engineered Cas9 nucleases are also conceivable. For example, see Slaymaker et al., Rationally engineered Cas9 nucleases with improved specificity, Science 351(6268):84-88(2016).

[0045] As used herein, the term "Cas9" refers to an RNA-inducible nuclease (e.g., of bacterial or archaeal origin, or derived therefrom). Exemplary RNA-inducible nucleases include the aforementioned Cas9 protein and its homologs. Other RNA-inducible nucleases include Cpf1 (e.g., see Zetsche et al., Cell, Volume 163, Issue 3, pp. 759-771, 22 October 2015) and its homologs.

[0046] As used herein, terms such as “ribonucleoprotein” refer to target-directed nucleases, such as complexes of Cas9 protein and sgRNA, Cas9 protein and crRNA, Cas9 protein and transactivating crRNA (tracrRNA), Cas9 protein and guide RNA, or combinations thereof (e.g., complexes containing Cas9 protein, tracrRNA, and crRNA-guide RNA). It should be understood that in some embodiments described herein, the Cas9 nuclease may be substituted with the Cpf1 nuclease or any other inducible nuclease.

[0047] As used herein, the term “complex-forming” refers to two or more molecules that physically associate via non-covalent interactions. For example, in the case of an RNA-induced nuclease that complexes with gRNA, the nuclease functionally associates with the gRNA via non-covalent interactions, facilitating the recruitment of the nuclease to a genomic locus targeted by the gRNA. Similarly, in the case of an RNA-induced nuclease that complexes with nucleic acid, the nuclease functionally associates with the nucleic acid via non-covalent interactions, facilitating the recruitment of the nucleic acid to a target genomic locus that can, for example, function as a template for homologous recombination repair (HDR).

[0048] As used herein, the terms “editing” or “modification” in the context of editing or modifying a cell’s genome refer to inducing a structural change in the genomic sequence of a target genomic region. For example, editing or modification may take the form of inserting a nucleotide sequence into the cell’s genome. For example, an exogenous transgene encoding a polypeptide may be inserted into the genomic sequence of a T cell receptor (TCR) locus on a T cell. As used throughout this application, “TCR locus” is the genomic location where a gene encoding a TCRα subunit, TCRβ subunit, TCRγ subunit, or TCRδ subunit is located. Such editing or modification may be carried out, for example, by inducing a double-strand break within a target genomic region, or by inducing a pair of single-strand nicks on opposing strands and framing them adjacent to the target genomic region. Methods for inducing single-strand or double-strand breaks at or within a target genomic region include the use of a Cas9 nuclease domain or a derivative thereof, and a pair of guide RNAs (e.g., sgRNA or crRNA:tracrRNA) or guide RNAs directed towards the target genomic region.

[0049] As used herein, the term “introduce” in the context of introducing nucleic acids or nucleic acid-containing complexes, such as the RNP-DNA template complex, refers to the transfer of a nucleic acid sequence or RNP-DNA template complex from the outside of a cell to the inside of a cell. In some cases, introduction refers to the transfer of a nucleic acid or complex from the outside of a cell to the inside of a cell nucleus. Various methods of such transfer are considered, including but not limited to, electroporation, contact with nanowires or nanotubes, receptor-mediated internal transfer, transfer via cell-permeable peptides, and liposome-mediated transfer.

[0050] As used herein, the term “exogenous” refers to something not typically found in nature. For example, the term “exogenous gene” refers to a gene not typically found in a given cell in nature.

[0051] As used herein, the term “transgene” refers to an exogenous gene artificially introduced into the genome of a cell, or an endogenous gene artificially introduced into a non-natural locus of the genome of a cell. A transgene may refer to a DNA fragment involved in the production or coding of polypeptide chains. A transgene may include the regions before and after the coding region (leader and trailer) and intervening sequences (introns) between the individual coding fragments (exons). Alternatively, a transgene may refer to a DNA fragment involved in the production or coding of non-coding RNA such as rRNA, tRNA, gRNA, siRNA, or miRNA.

[0052] As used herein, the term “housekeeping gene” refers to a gene that is necessary for basic cellular functions and is constitutively and stably expressed under a variety of physiological and experimental conditions. An example of a housekeeping gene is Gapdh.

[0053] As used herein, “cells” may be eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, etc. In some cases, cells are mammalian cells, e.g., human cells. In some cases, cells are immune cells. For example, in some embodiments, cells are human T cells (e.g., CD4+ or CD8+ T cells), or cells that can differentiate into T cells expressing TCR receptor molecules. These include hematopoietic stem cells and cells derived from hematopoietic stem cells. In some embodiments, cells are induced pluripotent stem cells (iPSCs). In some embodiments, cells are iPSC-derived natural killer cells (iNKs).

[0054] As used herein, the term "selectable marker" refers to a gene that enables the selection of host cells, such as T cells, that contain the marker. Selectable markers include, but are not limited to, fluorescent markers, luminescent markers, and drug selectable markers, cell surface receptors, and the like. In some embodiments, the selection can be a positive selection. That is, cells that express the marker are isolated from a population, for example, to create an enriched population of cells that express the selectable marker. The separation can be performed by any convenient separation technique suitable for the selectable marker used. For example, when using a fluorescent marker, the cells can be separated by fluorescence-activated cell sorting (FACS), but when a cell surface marker is inserted, affinity separation techniques, such as magnetic separation, affinity chromatography, "panning" with an affinity reagent bound to a solid matrix, FACS, or other convenient techniques can be used to separate the cells from a heterogeneous population.

[0055] As used herein, the term "hematopoietic stem cell" refers to a type of stem cell that is capable of giving rise to blood cells. Hematopoietic stem cells are capable of giving rise to cells of the myeloid or lymphoid lineage, or combinations thereof. Hematopoietic stem cells are found primarily in the bone marrow but can also be isolated from peripheral blood or fractions thereof. Various cell surface markers can be used to identify, sort, or purify hematopoietic stem cells. In some cases, hematopoietic stem cells are identified as + c-kit - and lin + In some cases, human hematopoietic stem cells are identified as CD34 + , CD59 + , Thy1 / CD90 lo / - , CD38 + , C-kit / CD117 - and lin - In some cases, human hematopoietic stem cells are identified as CD34 + , CD59 + , Thy1 / CD90 lo / - , CD38 + , C-kit / CD117- It is identified as. In some cases, human hematopoietic stem cells are CD133 + CD59 + Thy1 / CD90 + CD38 lo / - C-kit / CD117 + ,lin - It is identified as such. In some cases, mouse hematopoietic stem cells are CD34 lo / - SCA-1 + Thy1 + / lo CD38 + C-kit + ,lin - It is identified as such. In some cases, hematopoietic stem cells are CD150 + CD48 - CD244 - That is the case.

[0056] In this specification, the term “hematopoietic cells” refers to cells derived from hematopoietic stem cells. Hematopoietic cells may be obtained or provided by isolation from an organism, system, organ, or tissue (e.g., blood or a fraction thereof). Alternatively, hematopoietic cells may be obtained or provided by isolating hematopoietic stem cells and differentiating the stem cells. Hematopoietic cells include cells whose potential for differentiation into further cell types is limited. Such hematopoietic cells include, but are not limited to, multipotent progenitor cells, lineage-restricted progenitor cells, myeloid common progenitor cells, granulocyte-macrophage progenitor cells, or megakaryocyte-erythroblast progenitor cells. Hematopoietic cells include lymphoid and myeloid lineage cells such as lymphocytes, erythrocytes, granulocytes, monocytes, and platelets. In some embodiments, hematopoietic cells are immune cells such as T cells, B cells, macrophages, natural killer (NK) cells, or dendritic cells. In some embodiments, the cells are innate immune cells.

[0057] As used herein, the term “T cell” refers to lymphoid cells that express the TCR molecule. T cells include human alpha-beta (αβ) T cells and human gamma-delta (γδ) T cells. T cells include, but are not limited to, naive T cells, stimulated or activated T cells, primary T cells (e.g., uncultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, combinations thereof, or subpopulations thereof. T cells are CD4 + CD8 + , or CD4 + And CD8 + It is possible. T cells also have CD4 - CD8 - , or CD4 - And CD8 - It is possible. T cells are helper cells, for example, T H 1. T H 2, T H 3, T H 9, T H 17, or T FH It can be a type of helper cell. The T cell can be a cytotoxic T cell. Treg is FOXP3 + or FOXP3 - It is possible. T cells can be alpha / beta T cells or gamma / delta T cells. In some cases, T cells are CD4 + CD25 hi CD127 lo It is a Treg. In some cases, T cells are type 1 regulatory (Tr1), T H 3. Treg selected from a group consisting of CD8+CD28-, Treg17, and Qa-1-restricted T cells, or combinations thereof or subpopulations. In some cases, the T cell is FOXP3 + These are T cells. In some cases, T cells are CD4 + CD25 lo CD127 hi These are effector T cells. In some cases, T cells are CD4 + CD25 lo CD127hi CD45RA hi CD45RO - These are naive T cells. The T cells themselves may be genetically modified recombinant T cells.

[0058] As used herein, the term “primary” in the context of primary cells refers to cells that have not been transformed or immortalized. Such primary cells can be cultured, secondary cultured, or passaged a limited number of times (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 times). In some cases, primary cells adapt to in vitro culture conditions. In some cases, primary cells are isolated from organisms, systems, organs, or tissues, optionally sorted, and used directly without culture or secondary culture. In some cases, primary cells are stimulated, activated, or differentiated. For example, primary T cells can be activated by contact with (e.g., culture in the presence of) CD3 agonists, CD28 agonists, IL-2, IFN-γ, or combinations thereof.

[0059] As used herein, the terms “homologous recombination repair” or “HDR” refer to a cellular process in which a cleaved or nicked end of a DNA strand is repaired by polymerization from a homologous template nucleic acid. Thus, the original sequence is replaced with the template sequence. In some cases, an exogenous template nucleic acid, such as a DNA template, can be introduced to obtain specific HDR-induced changes in the sequence at a target site. In this way, specific mutations can be introduced into cleavage sites, for example, cleavage sites created by a target-directed nuclease. Single-stranded or double-stranded DNA templates can be used by cells as templates for editing or modifying the cell’s genome, for example, by HDR. Generally, a single-stranded or double-stranded DNA template has at least one region homologous to the target site. In some cases, a single-stranded or double-stranded DNA template has two homologous regions, e.g., a 5' end and a 3' end, adjacent to the region containing the DNA template to be inserted into the target cleavage or insertion site.

[0060] As used herein, the term “targeted insertion” refers to the incorporation of a molecule (e.g., a nucleic acid) into a specific location within a cell. In the case of nucleic acids, targeted insertion refers to the incorporation of a nucleic acid into a single-strand or double-strand break at a specific location in the cell’s genomic DNA, for example, via HDR, resulting in a continuous genomic DNA strand.

[0061] When used in the context of polynucleotide or polypeptide sequences, the terms “substantially identical” or “substantially identical” refer to sequences having at least 60% sequence identity with respect to a reference sequence. Alternatively, the identity percentage can be any integer between 60% and 100%. Exemplary embodiments include at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% compared to a reference sequence using the program described herein and preferably using BLAST with standard parameters as described below. Those skilled in the art will recognize that these values ​​can be appropriately adjusted, taking into account codon degeneracy, amino acid similarity, reading frame positioning, etc., to determine the corresponding identity of proteins encoded by two nucleotide sequences.

[0062] For sequence comparison, typically one sequence acts as a reference sequence, and the test sequence is compared to it. When using a sequence comparison algorithm, the test sequence and reference sequence are entered into a computer, subsequence coordinates are specified as needed, and the sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence to the reference sequence based on the program parameters.

[0063] The BLAST and BLAST 2.0 algorithms are preferred for determining sequence identity and sequence identity percentage, and are described in Altschul et al. (1990) J.Mol.Biol.215:403-410 and Altschul et al. (1977) Nucleic Acids Res.25:3389-3402, respectively. Software for performing BLAST analysis is publicly available on the National Center for Biotechnology Information (NCBI) website. This algorithm first identifies high-scoring sequence pairs (HSPs) by identifying shorter words W in the query sequence that match or satisfy some positive threshold score T when aligned with words of the same length in the database sequence. T is referred to as the neighbor word score threshold (Altschul et al, supra). These first neighbor word hits serve as seed values ​​to initiate a search to find longer HSPs that contain them. Word hits extend in both directions along each sequence as long as the cumulative alignment score can increase. For nucleotide sequences, the cumulative score is calculated using parameters M (reward score for matching residue pairs; always greater than 0) and N (penalty score for mismatched residues; always less than 0). For amino acid sequences, the cumulative score is calculated using a scoring matrix. The extension of word hits in each direction stops when the cumulative alignment score decreases by amount X from its maximum actual value, when the cumulative score becomes zero or less due to the accumulation of residue alignments with one or more negative scores, or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of alignment. The BLASTN program (for nucleotide sequences) uses a word length of 28 (W), an expected value of 10 (E), M=1, N=-2, and comparison of both strands by default.For amino acid sequences, the BLASTP program uses a word length of 3 (W), an expected value of 10 (E), and the BLOSUM62 scoring matrix (Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) by default.

[0064] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indicator of the probability that a match between two nucleotide or amino acid sequences occurs by chance. For example, when comparing a test nucleic acid with a reference nucleic acid, the minimum sum probability should be less than about 0.01, more preferably about 10. -5 Less than, most preferably about 10 -20 If it is less than [a certain value], it is considered similar to the reference array.

[0065] As used herein, the term “cancer-specific antigen” refers to an antigen that is specific to cancer cells or is expressed more abundantly in cancer cells than in non-cancer cells. In some embodiments, cancer-specific antigens are tumor-specific antigens.

[0066] As used herein, the terms “subject” and “patient” refer to an organism treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (e.g., mice, monkeys, horses, cattle, pigs, dogs, cats, etc.), and more preferably include humans.

[0067] Throughout this description, where a composition is described as having, including, or comprising certain components, or where a process and method is described as having, including, or comprising certain steps, it is intended that, in addition, there exist compositions of the present invention that are essentially composed of or comprise the described components, and there exist processes and methods of the present invention that are essentially composed of or comprise the described process steps.

[0068] I. Composition This specification provides compositions for targeted insertion of nucleic acids, including sequences having coding ability equivalent to the 3' or 5' portion of an endogenous gene within a cell, and exogenous transgenes. In some embodiments, the composition comprises (A) guide RNA (gRNA), (B) targeted nuclease, and (C) nucleic acid (e.g., a template for DNA repair). In another embodiment, the composition comprises (A) targeted nuclease, and (B) nucleic acid (e.g., a template for DNA repair).

[0069] A. Guide RNA As used herein, guide RNA (gRNA) is a nucleic acid that interacts with a site-specific nuclease or target-directed nuclease and specifically binds to or hybridizes with a target nucleic acid in the cellular genome, forming a complex with the gRNA and nuclease and co-localizing with the target nucleic acid in the cellular genome. In some embodiments, the gRNA includes a DNA targeting sequence or protospacer sequence approximately 10 to 50 nucleotides in length that specifically binds to or hybridizes with a target DNA sequence in the genome. For example, in some embodiments, the DNA targeting sequence is approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the gRNA includes a single guide RNA (sgRNA). In some embodiments, the gRNA includes a crRNA sequence and a transactivating crRNA tracrRNA sequence (crRNA:tracrRNA). In some embodiments, the gRNA does not include a tracrRNA sequence.

[0070] In some embodiments, the DNA targeting sequence is designed to complement (e.g., perfectly complement) or substantially complement the target DNA sequence. In some cases, the DNA targeting sequence may incorporate fluctuating or degenerate bases to bind multiple genetic elements. In some cases, the 19 nucleotides at the 3' or 5' end of the binding region are perfectly complementary to the target genetic element or multiple genetic elements. In some cases, the binding region can be modified to increase stability. For example, non-native nucleotides can be incorporated to increase RNA resistance to degradation. In some cases, the binding region can be modified or designed to avoid or reduce the formation of secondary structures in the binding region. In some cases, the binding region can be designed to optimize the GC content. In some cases, the GC content is preferably about 40% to about 60% (e.g., 40%, 45%, 50%, 55%, 60%).

[0071] In some embodiments, the DNA targeting sequence is complementary or substantially complementary to an endogenous gene within the cell. For example, in some embodiments, the DNA targeting sequence is complementary or substantially complementary to an endogenous gene encoding the T cell receptor alpha chain constant region (TRAC), T cell receptor beta chain constant region (TRBC), CD3γ chain, CD3δ chain, CD3ε chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). In certain embodiments, the DNA targeting sequence is complementary or substantially complementary to the endogenous I-TRAC and includes the sequence AAGTCTCTCAGCTGGTACA (SEQ ID NO: 1).

[0072] B. Targeted nucleases In some embodiments, the composition includes, but is not limited to, RNA-induced nucleases, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), or target-directed nucleases including megaTAL. For example, in some embodiments, the target-directed nuclease is an RNA-induced nuclease that forms a complex with gRNA and is induced by the gRNA to a target region in the cell's genome, where it introduces single-strand or double-strand breaks into the genomic DNA. For example, in certain embodiments, the target-directed nuclease is an RNA-induced nuclease. In some embodiments, the RNA-induced nuclease is a Cas9 nuclease.

[0073] In certain embodiments, the Cas9 protein may be in an active endonuclease form such that, when bound to a target nucleic acid as part of a complex with gRNA and / or as part of a complex with a nucleic acid (e.g., a DNA template), a double-strand break is introduced into the target nucleic acid. Compositions and methods provided herein allow for the introduction of a Cas9 polypeptide or a nucleic acid encoding a Cas9 polypeptide into cells. The double-strand break is repaired by HDR, and the DNA template is inserted into the cell's genome. Various Cas9 nucleases can be utilized in the methods described herein. For example, a Cas9 nuclease that requires a guide RNA with an NGG protospacer adjacent motif (PAM) located immediately 3' of the target region can be utilized. Such a Cas9 nuclease can target, for example, the region of exon 1 of a TRAC or exon 1 of a TRAB containing an NGG sequence. As another example, a Cas9 protein having an orthogonal PAM motif requirement can be utilized to target sequences that do not have an adjacent NGG PAM sequence. Exemplary Cas9 proteins with orthogonal PAM sequence specificity include, but are not limited to, those described in Esvelt et al., Nature Methods 10:1116-1121 (2013).

[0074] In some cases, the Cas9 protein is a nickase, thereby introducing a single-strand break or nick into the target nucleic acid when bound as part of a complex with a gRNA. A pair of Cas9 nickases bound to structurally different gRNAs can target two proximal sites in the target genomic region, potentially introducing a pair of proximal single-strand breaks into the target genomic region, e.g., exon 1 of the TRAC gene or exon 1 of the TRBC gene. Since off-target effects are generally likely to result in a single nick repaired without damage by the base excision repair mechanism, the nickase pair can provide enhanced specificity. Exemplary Cas9 nickases include Cas9 nucleases with D10A or H840A mutations. (See, e.g., Ran et al. "Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity," Cell 154(6):1380-1389 (2013)).

[0075] In another embodiment, the target-directed nuclease may be a TALEN, ZFN, or megaTAL (see, for example, Merkert and Martin, "Site-Specific Genome Engineering in Human Pluripotent Stem Cells," Int.J.Mol.Sci.18(7):1000 (2016)).

[0076] C. Nucleic acid In some embodiments, the composition further comprises a nucleic acid that forms a complex with an RNA-inducible nuclease, the nucleic acid comprising one or more regions homologous to the cell's endogenous gene, a sequence having coding ability equivalent to the 5' or 3' portion of the endogenous gene, and an exogenous transgene. In some embodiments, the nucleic acid functions as a template for DNA repair mechanisms such as HDR. For example, in some embodiments, the nucleic acid provided herein comprises one or more regions homologous to at least one region adjacent to a target cleavage site of the cell's endogenous gene, a sequence having coding ability equivalent to the 5' or 3' portion of the endogenous gene, and an exogenous transgene, wherein the sequence having coding ability equivalent to the 5' or 3' portion of the endogenous gene and the exogenous transgene are inserted into the target cleavage site in the cell's endogenous gene.

[0077] For example, in one embodiment, the nucleic acid includes, in order from 5' to 3', (i) a 5' homology arm having sequence homology or substantial sequence homology with the 5' portion of an endogenous gene in the cell, (ii) a sequence having coding ability equivalent to the 3' portion of an endogenous gene in the cell, having a stop codon and polyadenylation sequence encoding the carboxyl terminal portion of the protein product of the endogenous gene, (iii) an exogenous transgene, and (iv) a 3' homology arm having sequence homology or substantial sequence homology with the 3' portion of an endogenous gene in the cell. Upon introduction into cells, the 5' and 3' homology arms align the nucleic acid with the target endogenous gene. The sequence and exogenous transgene, which have equivalent coding ability to the 3' portion of the endogenous gene that encodes the carboxyl terminus of the endogenous gene's protein product, are inserted into the target cleavage site within the endogenous gene (e.g., introduced by a target-directed nuclease) via DNA repair mechanisms (e.g., homologous recombination repair (HDR)). The insertion of the sequence and exogenous transgene, which have equivalent coding ability to the 3' portion of the endogenous gene, results in the restoration or continuation of expression of the endogenous gene product and the expression of the exogenous transgene.

[0078] In another embodiment, the nucleic acid comprises, in 5' to 3' order, (i) a 5' homology arm having sequence homology or substantial sequence homology with the 5' portion of an endogenous gene within the cell, (ii) an exogenous transgene, (iii) a sequence having equivalent coding ability to the 5' portion of the endogenous gene and encoding the amino-terminal portion of the protein product of the endogenous gene, and (iv) a 3' homology arm having sequence homology or substantial sequence homology with the 3' portion of the endogenous gene within the cell. Upon introduction into a cell, the 5' and 3' homology arms align the nucleic acid with the target endogenous gene, and the exogenous transgene and the sequence having equivalent coding ability to the 5' portion of the endogenous gene and encoding the amino-terminal portion of the protein product of the endogenous gene are inserted into a target cleavage site within the endogenous gene (e.g., introduced by a target-directed nuclease) via a DNA repair mechanism (e.g., HDR). Insertion of sequences with coding ability equivalent to the 5' portion of exogenous transgenes and endogenous genes results in the restoration or continuation of expression of exogenous transgenes and endogenous gene products.

[0079] The concept of using targeted nucleases to deliver cleavage sites within genes encoding proteins involved in cell survival or proliferation (e.g., Gapdh, IL2RG, or TRAC) and introducing sequences with equivalent coding ability to the 3' or 5' portion of the survival gene, along with a desired exogenous transgene (e.g., CAR or gene circuit), can be generalized to all proteins involved in cell survival. In certain embodiments, cells receiving targeted nuclease activity either incorporate the desired transgene or fail to incorporate it, in order to restore the expression of the important protein. Sets of cells that do not undergo insertion lack the corresponding protein (e.g., IL2RG or other housekeeping genes) and become unable to survive. Cells that do not incorporate typically deplete the culture medium over time. On the other hand, cells that receive the desired transgene also restore the expression of the corresponding protein and are generally enriched in the culture during cultivation and preparation. Using this method, cells that successfully incorporate the exogenous transgene (e.g., CAR or gene circuit) generally exhibit preferential survival and enrichment. In some embodiments, the transgene may be a CAR, gene circuit, or any other payload to impart a desired function to the target cell. The target gene may, for example, encode any protein involved in the survival or proliferation of the cell being constructed. In the case of T cells, this may include one or more genes that constitute the TCR signaling complex, cytokine receptors, and their downstream signaling molecules, and / or any housekeeping genes involved in the survival or proliferation of T cells, such as TRAC, IL2RG, or Gapdh.

[0080] In some embodiments described herein, each of the one or more regions homologous to the endogenous gene is at least about 50, 100, 150, 200, 250, 300, 350, 400, or 450 nucleotides in length. In some embodiments, the one or more regions homologous to the endogenous gene are at least 80%, 90%, 95%, 99%, or 100% complementary to the endogenous gene. In some embodiments, the one or more homologous regions are homologous to the genomic sequence in human immune cells, such as T cells. In some embodiments, the one or more homologous regions are homologous to TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, CD3ξ chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG).

[0081] For example, in some embodiments, the homologous region of an endogenous gene is at least about 50, 100, 150, 200, 250, 300, 350, 400, or 450 nucleotides in length and may be at least 80%, 90%, 95%, 99%, or 100% complementary to any endogenous gene sequence in Table 1 across the length of the homologous region.

[0082] [Table 1]

[0083] In some embodiments, one or more homologous regions are homologous to the genomic sequences of one or more endogenous housekeeping genes. In some embodiments, one or more homologous regions are homologous to beta-actin (Actb), ATP synthase H +Transport is homologous to mitochondrial F0 complex subunit B1 (Atp5f1), beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphoribosyltransferase (Hprt), phosphoglycerate kinase I (Pgk1), peptidyl prolyl isomerase A (Ppia), ribosomal protein S18 (Rps18), TATA box-binding protein (Tbp), transferrin receptor (Tfrc), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase-activating protein zetapolypeptide (Ywhaz), Nanog homeobox (Nanog), zinc finger protein 42 (Rex1), or POU domain class 5 transcription factor 1 (Oct4).

[0084] For example, in some embodiments, homologous regions of endogenous housekeeping genes are at least about 50, 100, 150, 200, 250, 300, 350, 400, or 450 nucleotides in length and may be at least 80%, 90%, 95%, 99%, or 100% complementary to any endogenous gene sequence in Table 2 across the length of the homologous region.

[0085] [Table 2]

[0086] In some embodiments, the nucleic acid comprises a homologous recombination repair (HDR) template and one or more RNA-induced nuclease target sequences. In some embodiments, the nucleic acid comprises one RNA-induced nuclease target sequence and one or more protospacer adjacent motifs (PAMs). The complex comprising the RNA-induced nuclease, gRNA, and nucleic acid can move the HDR template to a desired intracellular location (e.g., the nucleus) without cleaving the RNA-induced nuclease target sequence, and the HDR template can be incorporated into the cleaved target site of the endogenous gene. In some embodiments, the RNA-induced nuclease target sequence and the PAM are located at the 5' end of the HDR template. In particular, in some embodiments, the PAM may be located at the 5' end of the RNA-induced nuclease target sequence. In another embodiment, the PAM may be located at the 3' end of the RNA-induced nuclease target sequence. In some embodiments, the RNA-induced nuclease target sequence and the PAM are located at the 3' end of the HDR template. In particular, in some embodiments, the PAM may be located at the 5' end of the RNA-induced nuclease target sequence. In another embodiment, the PAM is located at the 3' end of the RNA-induced nuclease target sequence. In some embodiments, the nucleic acid comprises two RNA-induced nuclease target sequences and two PAMs. In particular, in some embodiments, the first RNA-induced nuclease target sequence and the first PAM are located at the 5' end of the HDR template, and the second RNA-induced nuclease target sequence and the second PAM are located at the 3' end of the HDR template. In some embodiments, the first PAM is located at the 5' end of the first RNA-induced nuclease target sequence, and the second PAM is located at the 5' end of the second RNA-induced nuclease target sequence. In another embodiment, the first PAM is located at the 5' end of the first RNA-induced nuclease target sequence, and the second PAM is located at the 3' end of the second RNA-induced nuclease target sequence. In yet another embodiment, the first PAM is located at the 3' end of the first RNA-induced nuclease target sequence, and the second PAM is located at the 5' end of the second RNA-induced nuclease target sequence.In yet another embodiment, the first PAM is located at the 3' end of the first RNA-induced nuclease target sequence, and the second PAM is located at the 3' end of the second RNA-induced nuclease target sequence.

[0087] In some embodiments, the nucleic acids described herein include sequences having coding ability equivalent to the 3' portion of an endogenous gene within a cell. In certain embodiments, the sequences having coding ability equivalent to the 3' portion encode the carboxyl-terminal portion of the protein product of the endogenous gene. In some embodiments, the sequences having coding ability equivalent to the 3' portion of an endogenous gene include a stop codon and a polyadenylation sequence. In some embodiments, the sequences having coding ability equivalent to the 3' portion of an endogenous gene include the entire coding sequence 3' of the target cleavage site. For example, when inserted into a target cleavage site in an endogenous gene, the inserted sequences having coding ability equivalent to the 3' portion form a continuous open reading frame with the 5' portion of the endogenous gene located immediately 5' of the target cleavage, restoring or continuing the expression of the protein product encoded by the endogenous gene under the control of the endogenous promoter. In some embodiments, the sequences having coding ability equivalent to the 3' portion of an endogenous gene include sequences identical to the 3' portion of the endogenous gene located immediately 3' of the target cleavage site. In some embodiments, a sequence having coding ability equivalent to the 3' portion of an endogenous gene comprises the same sequence as the 3' portion of the endogenous gene located immediately 3' from the target cleavage site, and one or more alternative codons.

[0088] In some embodiments, the length of a sequence having coding ability equivalent to the 3' portion of an endogenous gene is approximately 1 to 2500 nucleotides. For example, the lengths of sequences having coding ability equivalent to the 3' portion of an endogenous gene are approximately 1 to 100, 1 to 200, 1 to 300, 1 to 400, 1 to 500, 1 to 600, 1 to 700, 1 to 800, 1 to 900, 1 to 1000, 100 to 2500, 200 to 2500, 300 to 2500, 400 to 2500, 500 to 2500, 600 to 2500, 700 to 2500, 800 to 2500, 900 to 2500, 1000 to 2500, 1100 to 2500, 1200 to 2500, and 130 0-2500, 1400-2500, 1500-2500, 1600-2500, 1700-2500, 1800-2500, 1900-2500, 2000-2500, 2100-2500, 2200-2500, 2300-2500, 2500-2500, 100-2000, 200-2000, 300-2000, 400-2000, 500-2000, 600-2000, 700-2000, 800-2000, 900-2000, 1000-2000, 1100 ~2000, 1200~2000, 1300~2000, 1400~2000, 1500~2000, 1600~2000, 1700~2000, 1800~2000, 1900~2000, 100~1500, 200~1500, 300~1500, 400~1500, 500~1500, 600~1500, 700~1500, 800~1500, 900~1500, 1000~1500, 1100~1500, 1200~1500, 1300~1500, 1400~ The lengths are 1500, 100-1250, 200-1250, 300-1250, 400-1250, 500-1250, 600-1250, 700-1250, 800-1250, 900-1250, 1000-1250, 1100-1250, 1200-1250, 100-1000, 200-1000, 300-1000, 400-1000, 500-1000, 600-1000, 700-1000, 800-1000, or 900-1000 nucleotides.

[0089] In some embodiments, sequences having equivalent coding ability to the 3' portion are approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the endogenous gene over the length of the 3' portion.

[0090] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 3' portion of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, CD3ξ chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). For example, sequences having coding ability equivalent to the 3' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with respect to the 3' portion of any of the sequences listed in Table 1.

[0091] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 3' portion of Actb, Atp5f1, B2m, Gapdh, Gusb, Hprt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4. For example, sequences having coding ability equivalent to the 3' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 3' portion of any of the sequences listed in Table 2.

[0092] In another embodiment, the nucleic acid described herein comprises a sequence having coding ability equivalent to the 5' portion of an endogenous gene within a cell. In certain embodiments, the sequence having coding ability equivalent to the 5' portion encodes the amino-terminal portion of the protein product of the endogenous gene. In some embodiments, the sequence having coding ability equivalent to the 5' portion of the endogenous gene comprises the entire coding sequence 5' of the target cleavage site. For example, when inserted into a target cleavage site in an endogenous gene, the inserted sequence having coding ability equivalent to the 5' portion forms a continuous open reading frame with the 3' portion of the endogenous gene located immediately 3' from the target cleavage, restoring or continuing the expression of the protein product encoded by the endogenous gene. In some embodiments, the expression of the protein product encoded by the endogenous gene is restored or continued under the control of an endogenous promoter. In another embodiment, an exogenous promoter is inserted into the target cleavage site and operably linked to the sequence having coding ability equivalent to the 5' portion of the endogenous gene to drive the expression of the protein product of the endogenous gene within the cell. In some embodiments, a sequence having coding ability equivalent to the 5' portion of an endogenous gene includes a sequence identical to the 5' portion of an endogenous gene located immediately 5' of the target cleavage site. In some embodiments, a sequence having coding ability equivalent to the 5' portion of an endogenous gene includes a sequence identical to the 5' portion of an endogenous gene located immediately 5' of the target cleavage site and one or more alternative codons.

[0093] In some embodiments, sequences with coding ability equivalent to the 5' portion of an endogenous gene are approximately 1 to 2500 nucleotides long. For example, sequences with coding ability equivalent to the 5' portion of an endogenous gene are approximately 1 to 100, 1 to 200, 1 to 300, 1 to 400, 1 to 500, 1 to 600, 1 to 700, 1 to 800, 1 to 900, 1 to 1000, 100 to 2500, 200 to 2500, 300 to 2500, 400 to 2500, 500 to 2500, 600 to 2500, 700 to 2500, 800 to 2500, 900 to 2500, 1000 to 2500, 1100 to 2500, 1200 to 2500, 130 0-2500, 1400-2500, 1500-2500, 1600-2500, 1700-2500, 1800-2500, 1900-2500, 2000-2500, 2100-2500, 2200-2500, 2300-2500, 2500-2500, 100-2000, 200-2000, 300-2000, 400-2000, 500-2000, 600-2000, 700-2000, 800-2000, 900-2000, 1000-2000, 1100 ~2000, 1200~2000, 1300~2000, 1400~2000, 1500~2000, 1600~2000, 1700~2000, 1800~2000, 1900~2000, 100~1500, 200~1500, 300~1500, 400~1500, 500~1500, 600~1500, 700~1500, 800~1500, 900~1500, 1000~1500, 1100~1500, 1200~1500, 1300~1500, 1400~ The lengths are 1500, 100-1250, 200-1250, 300-1250, 400-1250, 500-1250, 600-1250, 700-1250, 800-1250, 900-1250, 1000-1250, 1100-1250, 1200-1250, 100-1000, 200-1000, 300-1000, 400-1000, 500-1000, 600-1000, 700-1000, 800-1000, or 900-1000 nucleotides.

[0094] In some embodiments, sequences having equivalent coding ability to the 5' portion are approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the endogenous gene over the length of the 5' portion.

[0095] In some embodiments, sequences having coding ability equivalent to the 5' portion of an endogenous gene may be the 5' portion of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, CD3ξ chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). For example, sequences having coding ability equivalent to the 5' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 5' portion of any of the sequences listed in Table 1.

[0096] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 5' portion of Actb, Atp5f1, B2m, Gapdh, Gusb, Hprt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4. For example, sequences having coding ability equivalent to the 5' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 3' portion of any of the sequences listed in Table 2.

[0097] The nucleic acids described herein further include exogenous transgenes. In some embodiments, the exogenous transgene is inserted into a target cleavage site in an endogenous gene within a cell to express the transgene. In some embodiments, an exogenous promoter is inserted into the target cleavage site and operably linked to the exogenous transgene to drive the expression of the transgene within the cell.

[0098] In some embodiments, the exogenous transgene includes a sequence encoding one or more polypeptides expressed within the cell. For example, in some embodiments, the exogenous transgene includes a sequence encoding one or more proteins expressed on the surface of the cell membrane. In some embodiments, the exogenous transgene includes a sequence encoding a transmembrane protein or a fragment thereof. For example, in some embodiments, the exogenous transgene includes one or more sequences encoding a chimeric receptor, CD28, CD45, CD2, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD28, CD30, CD33, CD37, CD40, CD64, CD80, CD83, CD86, CD127, CD134, CD137, CD154, CIITA, 4-1BBL, PD-1, PD-1L, LIGHT, DAP10, DAP12, ICAM-1, LFA-1, LCK, TNFR2, ICOS, NKG2C, HLA-E, B7-H3, or beta-2-microglobulin. In some embodiments, the exogenous transgene includes sequences encoding cell surface markers that can be used as selectable markers for cells in which the transgene has been successfully inserted into the cell's genome. For example, in some embodiments, the exogenous transgene includes a sequence encoding epidermal growth factor receptor (EGFR) or a cleavage fragment thereof, which can be readily detected using an anti-EGFR antibody and flow cytometry. For example, in some embodiments, the exogenous transgene includes a sequence encoding cleavage EGFR having a nucleotide sequence according to SEQ ID NO: 16 in Table 3.

[0099] [Table 3]

[0100] In some embodiments, the exogenous transgene includes a sequence encoding a fluorescent protein (e.g., GFP or mCherry) that can be used as a selectable marker for cells in which the transgene has been successfully inserted into the cell's genome.

[0101] In some embodiments, the exogenous transgene includes a sequence encoding a synthetic antigen receptor, which is a chimeric antigen receptor (CAR) or SynNotch receptor. See, for example, Sadelain et al., Cancer Discov. 3(4):388-398 (2013), Srivastava Trends Immunol. 36(8):494-502 (2015), Toda et al. Science 361(6398):156-162 (2018), and Cho et al. Scientific Reports 8:3846 (2018) regarding CAR and SynNotch design and uses. In certain embodiments, the exogenous transgene includes a sequence encoding a chimeric antigen receptor (CAR). In some embodiments, the exogenous transgene includes a CAR that specifically recognizes cancer cell-associated targets such as CD19, BCMA, CD20, CD22, CD30, CD33, CD123, CD133, CEA, EGFR, EGFRvIII, EphA2, ErbB family, GPC3, HER2, FAP, FRα, FD2, Igχ, IL-13α2, mesothelin, Muc1, PSMA, ROR1, VEGFR2, B7-H3, B7H6, CD5, CD23, CD70, CSPG4, EpCAM, GD3, HLA-A1+MAGE, IL-11Rα, Lewis-Y, Muc16, NKG2D ligand, PSCA, or TAG72. For example, in some embodiments, the exogenous transgene includes a sequence encoding CD19-CD28-CD3ξCAR, CD19-4-1BB-CD3ξCAR, MSLN-CD28-CD3ξCAR, or MSLN-4-1BB-CD3ξCAR.

[0102] In some embodiments, an exogenous transgene encodes one or more proteins that alter cellular function. For example, in the case of an exogenous transgene encoding a CAR inserted into the T cell genome, the expression of the CAR can alter the specificity and function of the T cell.

[0103] In another embodiment, the exogenous transgene encodes one or more cytoplasmic proteins, intracellular proteins, or soluble proteins. In some embodiments, the exogenous transgene encodes a therapeutic protein. In some embodiments, the exogenous transgene encodes a cytokine or a functional fragment thereof. In some embodiments, the exogenous transgene encodes a transcription factor. In some embodiments, the exogenous transgene encodes an immune checkpoint inhibitor.

[0104] In another embodiment, the exogenous transgene may include a sequence encoding non-coding RNA such as rRNA, tRNA, gRNA, siRNA, or miRNA.

[0105] In some embodiments, nucleic acids are introduced into cells as linear DNA templates. In some embodiments, nucleic acids are introduced into cells as double-stranded DNA templates. In another embodiment, the DNA template is a single-stranded DNA template. In some embodiments, the DNA template is a double-stranded or single-stranded plasmid.

[0106] In some embodiments, the nucleic acid includes one or more 2A sequences to facilitate the simultaneous translation of two or more protein products. For example, in some embodiments, one or more 2A sequences may be sequences following Sequence ID No. 14 or Sequence ID No. 15 in Table 4.

[0107] [Table 4]

[0108] For example, in some embodiments, the nucleic acid may be a plasmid having a sequence according to SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 33 in Table 5.

[0109] [Table 5] TIFF2023548478000007.tif237165TIFF2023548478000008.tif240165TIFF202 3548478000009.tif242165TIFF2023548478000010.tif236165TIFF2023548478 000011.tif240165TIFF2023548478000012.tif239165TIFF2023548478000013. tif240165TIFF2023548478000014.tif64165TIFF2023548478000015.tif239165 TIFF2023548478000016.tif241165TIFF2023548478000017.tif241165TIFF202 3548478000018.tif241165TIFF2023548478000019.tif64165TIFF20235484780 00020.tif239165TIFF2023548478000021.tif239165TIFF2023548478000022.t if240165TIFF2023548478000023.tif240165TIFF2023548478000024.tif212165

[0110] II.Cells The disclosure also provides cells comprising nucleic acids including the 5' portion of an endogenous gene, the 3' portion of an endogenous gene, an exogenous sequence having equivalent coding ability to the 5' portion of an endogenous gene or the 3' portion of an endogenous gene, and an exogenous transgene, wherein the cells express the endogenous gene and the exogenous transgene, respectively. In some embodiments, the cells disclosed herein are produced by introducing the aforementioned composition comprising gRNA, a target-directed nuclease, and nucleic acids into cells.

[0111] In some embodiments, the cells disclosed herein comprise nucleic acids comprising, from 5' to 3', (1) a sequence encoding the 5' portion of the cell's endogenous gene, (2) a sequence having equivalent coding ability to the 3' portion of the cell's endogenous gene, (3) a sequence encoding an exogenous transgene, and (4) a sequence encoding the 3' portion of the cell's endogenous gene, wherein the cells express (a) the endogenous gene encoded by (1) and (2) and (b) the exogenous transgene encoded by (3).

[0112] In another embodiment, the cells disclosed herein comprise nucleic acids comprising, 5' to 3', (a) a sequence encoding the 5' portion of the cell's endogenous gene, (2) a sequence encoding an exogenous transgene, (3) a sequence having equivalent coding ability to the 5' portion of the cell's endogenous gene, and (4) a sequence encoding the 3' portion of the cell's endogenous gene, wherein the cells express the (a) exogenous transgene encoded by (2) and the (b) endogenous gene encoded by (3) and (4).

[0113] In certain embodiments, a sequence having coding ability equivalent to the 3' portion encodes the carboxyl terminal portion of the protein product of the endogenous gene. In some embodiments, a sequence having coding ability equivalent to the 3' portion of the endogenous gene includes the entire coding sequence 3' of the target cleavage site. For example, if sequences having coding ability equivalent to the 3' portion are consecutive and operably linked to the 5' portion of the endogenous gene, the cell expresses the protein product encoded by the endogenous gene under the control of the endogenous promoter. In some embodiments, a sequence having coding ability equivalent to the 3' portion of the endogenous gene includes the same sequence as the 3' portion of the endogenous gene located immediately 3' of the target cleavage site. In some embodiments, a sequence having coding ability equivalent to the 3' portion of the endogenous gene includes the same sequence as the 3' portion of the endogenous gene located immediately 3' of the target cleavage site and one or more alternative codons.

[0114] In some embodiments, the length of a sequence having coding ability equivalent to the 3' portion of an endogenous gene is approximately 1 to 2500 nucleotides. For example, the lengths of sequences having coding ability equivalent to the 3' portion of an endogenous gene are approximately 1 to 100, 1 to 200, 1 to 300, 1 to 400, 1 to 500, 1 to 600, 1 to 700, 1 to 800, 1 to 900, 1 to 1000, 100 to 2500, 200 to 2500, 300 to 2500, 400 to 2500, 500 to 2500, 600 to 2500, 700 to 2500, 800 to 2500, 900 to 2500, 1000 to 2500, 1100 to 2500, 1200 to 2500, and 130 0-2500, 1400-2500, 1500-2500, 1600-2500, 1700-2500, 1800-2500, 1900-2500, 2000-2500, 2100-2500, 2200-2500, 2300-2500, 2500-2500, 100-2000, 200-2000, 300-2000, 400-2000, 500-2000, 600-2000, 700-2000, 800-2000, 900-2000, 1000-2000, 1100 ~2000, 1200~2000, 1300~2000, 1400~2000, 1500~2000, 1600~2000, 1700~2000, 1800~2000, 1900~2000, 100~1500, 200~1500, 300~1500, 400~1500, 500~1500, 600~1500, 700~1500, 800~1500, 900~1500, 1000~1500, 1100~1500, 1200~1500, 1300~1500, 1400~ The lengths are 1500, 100-1250, 200-1250, 300-1250, 400-1250, 500-1250, 600-1250, 700-1250, 800-1250, 900-1250, 1000-1250, 1100-1250, 1200-1250, 100-1000, 200-1000, 300-1000, 400-1000, 500-1000, 600-1000, 700-1000, 800-1000, or 900-1000 nucleotides.

[0115] In some embodiments, sequences having equivalent coding ability to the 3' portion are approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the endogenous gene over the length of the 3' portion.

[0116] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 3' portion of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, CD3ξ chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). For example, sequences having coding ability equivalent to the 3' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with respect to the 3' portion of any of the sequences listed in Table 1.

[0117] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 3' portion of Actb, Atp5f1, B2m, Gapdh, Gusb, Hprt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4. For example, sequences having coding ability equivalent to the 3' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 3' portion of any of the sequences listed in Table 2.

[0118] In certain embodiments, a sequence having coding ability equivalent to the 5' portion encodes the amino-terminal portion of the protein product of the endogenous gene. In some embodiments, a sequence having coding ability equivalent to the 5' portion of the endogenous gene includes the entire 5' coding sequence of the target cleavage site. For example, if sequences having coding ability equivalent to the 5' portion are consecutive and operably linked to the 3' portion of the endogenous gene, the cell expresses the protein product encoded by the endogenous gene under the control of an endogenous promoter. In another embodiment, the protein product of the endogenous gene is expressed under the regulation of an exogenously introduced promoter. In some embodiments, a sequence having coding ability equivalent to the 5' portion of the endogenous gene includes the same sequence as the 5' portion of the endogenous gene located immediately 5' of the target cleavage site. In some embodiments, a sequence having coding ability equivalent to the 5' portion of the endogenous gene includes the same sequence as the 5' portion of the endogenous gene located immediately 5' of the target cleavage site and one or more alternative codons.

[0119] In some embodiments, sequences having coding ability equivalent to the 5' portion of an endogenous gene are approximately 1 to 2500 nucleotides long. For example, sequences having coding ability equivalent to the 5' portion of an endogenous gene are approximately 1 to 100, 1 to 200, 1 to 300, 1 to 400, 1 to 500, 1 to 600, 1 to 700, 1 to 800, 1 to 900, 1 to 1000, 100 to 2500, 200 to 2500, 300 to 2500, 400 to 2500, 500 to 2500, 600 to 2500, 700 to 2500, 800 to 2500, 900 to 2500, 1000 to 2500, 1100 to 2500, 1200 to 2500, 1300~2500, 1400~2500, 1500~2500, 1600~2500, 1700~2500, 1800~2500, 1900~2500, 2000~2500, 2100~2500, 2200~2500, 2300~2500, 2500~2500, 100~2000, 200~2000, 300~2000, 400~2000, 500~2000, 600~2000, 700~2000, 800~2000, 900~2000, 1000~2000, 1 100-2000, 1200-2000, 1300-2000, 1400-2000, 1500-2000, 1600-2000, 1700-2000, 1800-2000, 1900-2000, 100-1500, 200-1500, 300-1500, 400-1500, 500-1500, 600-1500, 700-1500, 800-1500, 900-1500, 1000-1500, 1100-1500, 1200-1500, 1300-1500, 14 The ranges are 00-1500, 100-1250, 200-1250, 300-1250, 400-1250, 500-1250, 600-1250, 700-1250, 800-1250, 900-1250, 1000-1250, 1100-1250, 1200-1250, 100-1000, 200-1000, 300-1000, 400-1000, 500-1000, 600-1000, 700-1000, 800-1000, or 900-1000 nucleotides.

[0120] In some embodiments, sequences having equivalent coding ability to the 5' portion are approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the endogenous gene over the length of the 5' portion.

[0121] In some embodiments, sequences having coding ability equivalent to the 5' portion of an endogenous gene may be the 5' portion of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, CD3ξ chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). For example, sequences having coding ability equivalent to the 5' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 5' portion of any of the sequences listed in Table 1.

[0122] In some embodiments, sequences having coding ability equivalent to the 3' portion of an endogenous gene may be the 5' portion of Actb, Atp5f1, B2m, Gapdh, Gusb, Hprt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4. For example, sequences having coding ability equivalent to the 5' portion may have nucleotide sequences with approximately 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the 3' portion of any of the sequences listed in Table 2.

[0123] The cells disclosed herein further include exogenous transgenes. In some embodiments, the exogenous transgenes are expressed under the control of an endogenous promoter. In other embodiments, the exogenous transgenes are expressed under the control of an exogenously introduced and operablely linked promoter.

[0124] In some embodiments, the exogenous transgene includes a sequence encoding one or more polypeptides expressed within the cell. For example, in some embodiments, the exogenous transgene includes a sequence encoding one or more proteins expressed on the surface of the cell membrane. In some embodiments, the exogenous transgene includes a sequence encoding a transmembrane protein or a fragment thereof. For example, in some embodiments, the exogenous transgene includes one or more sequences encoding D28, CD45, CD2, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD28, CD30, CD33, CD37, CD40, CD64, CD80, CD83, CD86, CD127, CD134, CD137, CD154, CIITA, 4-1BBL, PD-1, PD-1L, LIGHT, DAP10, DAP12, ICAM-1, LFA-1, LCK, TNFR2, ICOS, NKG2C, HLA-E, B7-H3, or beta-2-microglobulin. In some embodiments, the exogenous transgene includes sequences encoding cell surface markers that can be used as selectable markers for cells in which the transgene has been successfully inserted into the cell's genome. For example, in some embodiments, the exogenous transgene includes a sequence encoding epidermal growth factor receptor (EGFR) or a cleavage fragment thereof, which can be readily detected using an anti-EGFR antibody and flow cytometry.

[0125] In some embodiments, the exogenous transgene includes a sequence encoding a synthetic antigen receptor, which is a chimeric antigen receptor (CAR) or SynNotch receptor. See, for example, Sadelain et al., Cancer Discov. 3(4):388-398 (2013), Srivastava Trends Immunol. 36(8):494-502 (2015), Toda et al. Science 361(6398):156-162 (2018), and Cho et al. Scientific Reports 8:3846 (2018) regarding CAR and SynNotch design and uses. In certain embodiments, the exogenous transgene includes a sequence encoding a chimeric antigen receptor (CAR). In some embodiments, the exogenous transgene includes a CAR that specifically recognizes cancer cell-associated targets such as CD19, BCMA, CD20, CD22, CD30, CD33, CD123, CD133, CEA, EGFR, EGFRvIII, EphA2, ErbB family, GPC3, HER2, FAP, FRα, FD2, Igχ, IL-13α2, mesothelin, Muc1, PSMA, ROR1, VEGFR2, B7-H3, B7H6, CD5, CD23, CD70, CSPG4, EpCAM, GD3, HLA-A1+MAGE, IL-11Rα, Lewis-Y, Muc16, NKG2D ligand, PSCA, or TAG72. For example, in some embodiments, the exogenous transgene includes a sequence encoding CD19-CD28-CD3ξCAR, CD19-4-1BB-CD3ξCAR, MSLN-CD28-CD3ξCAR, or MSLN-4-1BB-CD3ξCAR.

[0126] In some embodiments, an exogenous transgene encodes one or more proteins that alter cellular function. For example, in the case of an exogenous transgene encoding a CAR inserted into the T cell genome, the expression of the CAR can alter the specificity and function of the T cell.

[0127] In another embodiment, the exogenous transgene encodes one or more cytoplasmic proteins, intracellular proteins, or soluble proteins. In some embodiments, the exogenous transgene encodes a therapeutic protein. In some embodiments, the exogenous transgene encodes a cytokine or a functional fragment thereof. In some embodiments, the exogenous transgene encodes a transcription factor. In some embodiments, the exogenous transgene encodes an immune checkpoint inhibitor.

[0128] In another embodiment, the exogenous transgene may include a sequence encoding non-coding RNA such as rRNA, tRNA, gRNA, siRNA, or miRNA.

[0129] In some embodiments, the cells described herein are mammalian cells. For example, in some embodiments, the mammalian cells are human cells. In some embodiments, the human cells are pluripotent stem cells or induced pluripotent stem cells (iPSCs). In some embodiments, the human cells are T cells, B cells, natural killer (NK) cells, myeloid cells, macrophages, dendritic cells, hematopoietic stem cells, or other immune cells. In some embodiments, the T cells are regulatory T cells, effector T cells, or naive T cells. In some embodiments, the effector T cells are CD8+ T cells or CD4+ T cells. In some embodiments, the effector T cells are CD8+CD4+ T cells. In some embodiments, the T cells are T cells expressing the TCR receptor or T cells that differentiate into T cells expressing the TCR receptor. In some embodiments, the human cells are iPSC-derived NK cells. In some embodiments, the cells are primary cells. In some embodiments, the cells are obtained from a subject. For example, in some embodiments, cells are obtained from a subject and modified ex vivo by introducing the compositions described herein.

[0130] III. Genome Editing Methods This specification also provides a method for editing the genome of a cell, comprising introducing into the cell a composition for targeted insertion of nucleic acids comprising a sequence encoding the 3' or 5' portion of an endogenous gene of the cell and an exogenous transgene. In some embodiments, the method for editing the genome of a cell comprises introducing into the cell a composition comprising (A) guide RNA (gRNA), (B) targeted nuclease, and (C) nucleic acid (e.g., a template for DNA repair). In another embodiment, the method for editing the genome of a cell comprises introducing into the cell a composition comprising (A) targeted nuclease and (B) nucleic acid (e.g., a template for DNA repair).

[0131] In some embodiments, the method for editing the genome of a cell disclosed herein is, gRNAs that target endogenous genes within cells; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid that forms a complex with an RNA-inducible nuclease and comprises one or more regions homologous to an endogenous gene, a sequence having coding ability equivalent to the 3' portion of the endogenous gene, and an exogenous transgene. This includes introducing the RNA-induced nuclease into cells. In some embodiments, the RNA-induced nuclease specifically cleaves an endogenous gene within the cell to create an insertion site, into which a sequence having coding ability equivalent to the 3' portion of the endogenous gene and an exogenous transgene are inserted, resulting in the restoration or continuation of endogenous gene expression and the expression of the exogenous transgene in the cell.

[0132] In another embodiment, a method for editing the genome of a cell disclosed herein is: gRNAs that target endogenous genes within cells; RNA-inducible nucleases that form complexes with gRNA; and A nucleic acid that forms a complex with an RNA-inducible nuclease and comprises one or more regions homologous to an endogenous gene, an exogenous transgene, and a sequence having coding ability equivalent to the 5' portion of the endogenous gene. This includes introducing the RNA-induced nuclease into cells. In some embodiments, the RNA-induced nuclease specifically cleaves an endogenous gene within the cell to create an insertion site, into which an exogenous transgene and a sequence having coding ability equivalent to the 5' portion of the endogenous gene are inserted, resulting in the restoration or continuation of endogenous gene expression and the expression of the exogenous transgene in the cell.

[0133] In some embodiments, gRNA, RNA-inducible nucleases, and nucleic acids are introduced into cells via non-viral delivery. For example, in some embodiments, gRNA, RNA-inducible nucleases, and nucleic acids are introduced into cells via electroporation. In some embodiments, gRNA, RNA-inducible nucleases, and / or nucleic acids are introduced into cells via viral delivery. For example, in some embodiments, gRNA, RNA-inducible nucleases, and / or nucleic acids are introduced into cells via viral transduction (e.g., retrovirus, adenovirus, lentivirus, or adeno-associated virus). In some embodiments, gRNA, RNA-inducible nucleases, and / or nucleic acids are introduced into cells via adeno-associated viruses (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13).

[0134] For example, in some embodiments, a gRNA, a target-directed nuclease (e.g., an RNA-inducible nuclease), and a nucleic acid sequence are introduced into a cell as a ribonucleoprotein (RNP)-DNA complex, the RNP-DNA complex comprising (i) an RNP containing an RNA-inducible nuclease (e.g., Cas9) and a gRNA, and (ii) a nucleic acid that functions as a DNA template.

[0135] In some embodiments, the molar ratio of RNP to nucleic acid can range from approximately 3:1 to approximately 100:1. For example, the molar ratio can be approximately 5:1 to 10:1, approximately 5:1 to 15:1, 5:1 to 20:1, 5:1 to 25:1, approximately 8:1 to 12:1, approximately 8:1 to 15:1, approximately 8:1 to 20:1, or approximately 8:1 to 25:1.

[0136] In some embodiments, the nucleic acid concentration in the RNP-DNA template complex is approximately 2.5 pM to approximately 25 pM. In some embodiments, the amount of nucleic acid is approximately 1 μg to approximately 10 μg.

[0137] In some embodiments, the RNP-DNA complex is formed by incubating RNP with nucleic acid at a temperature of about 20°C to about 25°C for about 1 minute to less than 30 minutes. In some embodiments, the RNP-DNA complex and cells are mixed before introducing the RNP-DNA complex into the cells.

[0138] In some embodiments, nucleic acid sequences or RNP-DNA complexes are introduced into cells by electroporation. Methods, compositions, and apparatus for introducing RNP-DNA complexes by electroporation of cells may include those described in the examples herein. Additional or alternative methods, compositions, and apparatus for introducing RNP-DNA complexes by electroporation of cells may include those described in WO / 2006 / 001614 or Kim, JA et al. Biosens. Bioelectron. 23, 1353-1360 (2008). Additional or alternative methods, compositions, and apparatus for introducing RNP-DNA complexes by electroporation of cells may include those described in U.S. Patent Publication No. 2006 / 0094095, No. 2005 / 0064596, or No. 2006 / 0087522. Additional or alternative methods, compositions, and apparatus for electroporating cells to introduce RNP-DNA complexes may include those described in Li, LHet al. Cancer Res. Treat. l, 341-350 (2002), U.S. Patents 6,773,669, 7,186,559, 7,771,984, 7,991,559, 6485961, 7029916, and U.S. Patent Publications 2014 / 0017213 and 2012 / 0088842. Additional or alternative methods, compositions, and apparatus for electroporating cells to introduce RNP-DNA complexes may include those described in Geng, T. et al. J. Control Release 144, 91-100 (2010) and Wang, J., et al. Lab. Chip 10, 2057-2061 (2010). In some embodiments, RNP is delivered to cells in the presence of an anionic polymer. In some embodiments, the anionic polymer is an anionic polypeptide or anionic polysaccharide. In some embodiments, the anionic polymer is an anionic polypeptide (e.g., polyglutamic acid (PGA), polyaspartic acid, or polycarboxyglutamic acid). In some embodiments, the anionic polymer is anionic polysaccharide (e.g., hyaluronic acid (HA), heparin, heparin sulfate, or glycosaminoglycan).In some embodiments, the anionic polymer is poly(acrylic acid) (PAA), poly(methacrylic acid) (PMAA), poly(styrene sulfonic acid), or polyphosphate. In some embodiments, the anionic polymer has a molecular weight of at least 15 kDa (e.g., between 15 kDa and 50 kDa). In some embodiments, the anionic polymer and the RNA-inducible nuclease have a molar ratio of 10:1 to 120:1, respectively (e.g., 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, 110:1, or 120:1). In some embodiments, the molar ratio of gRNA to RNA-induced nuclease is between 0.25:1 and 4:1 (e.g., 0.25:1, 0.5:1, 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2:1, 2.2:1, 2.4:1, 2.6:1, 2.8:1, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, or 4:1).

[0139] In some embodiments, the nucleic acid or RNP-DNA complex is approximately 1 × 10⁶ 5 ~About 100×10 6 It is introduced into individual cells (e.g., T cells). For example, nucleic acids or RNP-DNA complexes are approximately 1 × 10⁻⁶ 5 Individual cells ~ approximately 5 x 10 5 Each cell is approximately 1 x 10⁻⁶ 5 Individual cells ~ approximately 1 × 10⁻⁶ 6 Individual cells, 1 × 10 5 Individual cells ~ approximately 1.5 × 10⁻⁶ 6 Individual cells, 1 × 10 5 Individual cells ~ approximately 2 × 10⁻⁶ 6 Each cell is approximately 1 x 10⁻⁶ 6 Individual cells ~ approximately 1.5 × 10⁻⁶ 6 A single cell, or approximately 1 × 10⁶ 6 Individual cells ~ approximately 2 × 10⁻⁶ 6 It is introduced into individual cells.

[0140] In some embodiments of the methods disclosed herein, upon introduction into cells, the RNP-DNA complex migrates to the locus of an endogenous gene within the cell, where a target-directed nuclease (e.g., RNA-inducible nuclease 9) is induced by the DNA-targeting sequence of the gRNA to introduce a double-strand break in the genomic DNA at the target break site. In certain embodiments, one or more regions homologous to the cell's endogenous gene align the nucleic acid with the cell's endogenous gene, causing, via HDR, the insertion of an exogenous transgene and a sequence having coding ability equivalent to the 3' portion of the cell's endogenous gene encoding the carboxyl terminus of the protein product of the endogenous gene into the target break site within the endogenous gene. In some embodiments, the inserted sequence having coding ability equivalent to the 3' portion forms a continuous open reading frame with the 5' portion of the endogenous gene located immediately 5' from the target break, restoring or continuing the expression of the protein product encoded by the endogenous gene under the control of the endogenous promoter. In some embodiments, an exogenous transgene is inserted, and the protein product encoded by the transgene (e.g., CAR) is expressed. In some embodiments, the exogenous transgene is expressed intracellularly under the control of an endogenous promoter. In some embodiments, the exogenous promoter is operably ligated to the exogenous transgene and inserted together with the exogenous transgene at a target cleavage site to drive the expression of the transgene in the cell.

[0141] In another embodiment of the method disclosed herein, upon introduction into cells, the RNP-DNA complex migrates to the locus of an endogenous gene within the cell, where a target-directed nuclease (e.g., an RNA-inducible nuclease) is induced by the DNA-targeting sequence of the gRNA to introduce a double-strand break in the genomic DNA at the target break site. In certain embodiments, one or more regions homologous to the cell's endogenous gene align the nucleic acid with the cell's endogenous gene, causing, via HDR, insertion of a sequence having coding ability equivalent to the 5' portion of the cell's endogenous gene that encodes the exogenous transgene and the amino-terminal portion of the protein product of the endogenous gene at the target break site of the endogenous gene. In some embodiments, the inserted sequence having coding ability equivalent to the 5' portion forms a continuous open reading frame with the 3' portion of the endogenous gene located immediately 3' from the target break, restoring or continuing the expression of the protein product encoded by the endogenous gene. In some embodiments, an exogenous transgene is inserted, and the protein product encoded by the transgene (e.g., CAR) is expressed. In some embodiments, the exogenous transgene is expressed under the control of the endogenous promoter of the intracellular endogenous gene. In another embodiment, the exogenous promoter is operably ligated to the exogenous transgene and inserted together with the exogenous transgene at a target cleavage site to drive the expression of the transgene in the cell. In some embodiments, the intracellular endogenous gene is expressed under the control of the endogenous promoter. In another embodiment, the exogenous promoter is operably ligated to a sequence having coding ability equivalent to the 5' portion of the endogenous gene and inserted together with the sequence having coding ability equivalent to the 5' portion of the endogenous gene at a target cleavage site to drive the expression of the intracellular endogenous gene.

[0142] In some embodiments, a method for editing the genome of a cell includes introducing a composition disclosed herein into a mammalian cell. For example, in some embodiments, the mammalian cell is a human cell, e.g., an immune cell. In certain embodiments, the immune cell is a T cell, e.g., a CD4+ or CD8+ T cell. In some embodiments, a method for editing the genome of a cell includes inserting an exogenous transgene into a genomic locus of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain (IL2RG). For example, in certain embodiments, the exogenous transgene is inserted into a target cleavage site within TRAC. In some embodiments, a method for editing the genome of a cell includes restoring or continuing the expression of an endogenous gene whose expression is interrupted by the insertion of the exogenous transgene. For example, the methods disclosed herein can restore or maintain the expression of TRAC, TRBC, CD3γ chain, CD3δ chain, CD3ε chain, IL-2Rα chain, IL-2Rβ chain, or IL-2Rγ chain.

[0143] In some embodiments, a method for editing the genome of a cell includes inserting an exogenous transgene into at least one genomic locus from among Actb, Atp5f1, B2m, Gapdh, Gusb, HPrt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4. In some embodiments, a method for editing the genome of a cell includes restoring or continuing the expression of an endogenous gene whose expression is interrupted by the insertion of the exogenous transgene. For example, the methods disclosed herein can restore or continue the expression of Actb, Atp5f1, B2m, Gapdh, Gusb, HPrt, Pgk1, Ppia, Rps18, Tbp, Tfrc, Ywhaz, Nanog, Rex1, or Oct4.

[0144] In an alternative embodiment, the method for editing the genome of a cell disclosed herein is: Target-directed nucleases selected from TALEN, ZFN, or megaTAL; and A nucleic acid that forms a complex with a target-directed nuclease and comprises one or more regions homologous to an endogenous gene, a sequence having coding ability equivalent to the 3' portion of the endogenous gene, and an exogenous transgene. This includes introducing the nuclease into cells. In some embodiments, the target-directed nuclease specifically cleaves an endogenous gene within the cell to create an insertion site, into which a sequence having coding ability equivalent to the 3' portion of the endogenous gene and an exogenous transgene are inserted, resulting in the restoration or continuation of endogenous gene expression and the expression of the exogenous transgene in the cell.

[0145] In yet another embodiment, a method for editing the genome of a cell disclosed herein is: Target-directed nucleases selected from TALEN, ZFN, or megaTAL; and A nucleic acid that forms a complex with a target-directed nuclease and comprises one or more regions homologous to an endogenous gene, an exogenous transgene, and a sequence having coding ability equivalent to the 5' portion of the endogenous gene. This includes introducing the nuclease into cells. In some embodiments, the target-directed nuclease specifically cleaves an endogenous gene within the cell to create an insertion site, into which an exogenous transgene and a sequence having coding ability equivalent to the 5' portion of the endogenous gene are inserted, resulting in the restoration or continuation of endogenous gene expression and the expression of the exogenous transgene in the cell.

[0146] IV. Treatment method Furthermore, this disclosure also provides methods for treating or preventing a disease in question, including editing the genome of cells by the methods disclosed herein and / or administering the cells disclosed herein to the target.

[0147] For example, in some embodiments, a method for treating or preventing a target disease includes obtaining cells containing nucleic acids, which include the 5' portion of an endogenous gene, the 3' portion of an endogenous gene, a sequence having coding ability equivalent to the 5' or 3' portion of an endogenous gene, and an exogenous transgene, and administering the cells to a target.

[0148] In some embodiments, the genomes of immune cells, such as T cells, can be edited using the methods and compositions described herein. In some embodiments, the immune cells (e.g., T cells) are obtained from subjects who have a disease or are at risk of developing a disease. For example, in some embodiments, immune cells (e.g., T cells) having genomes edited using the methods and compositions described herein can be administered to a subject to treat or prevent diseases in the subject, such as cancer, infection, autoimmune disease, transplant rejection, graft-versus-host disease, or other inflammatory disorders. In some embodiments, the expression of an exogenous transgene alters the specificity and / or functionality of the cells so that they treat and / or prevent a disease in the subject. For example, in some embodiments, T cells (e.g., CD4+ or CD8+ T cells) are obtained from a subject, their genomes are edited to express a CAR, and the CAR-expressing T cells are administered to a subject for the treatment of cancer. In certain embodiments, the methods disclosed herein are for the treatment or prevention of cancer in a subject, and the CAR recognizes a cancer-specific antigen (e.g., a tumor-specific antigen or a neoplastic antigen). In certain embodiments, the methods disclosed herein are for the treatment or prevention of autoimmune diseases in subjects, wherein the CAR recognizes antigens associated with autoimmune diseases.

[0149] In certain embodiments, the methods disclosed herein can be used to treat or prevent cancer in a subject, such as bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma, leukemia, lung cancer, lymphoma, mesothelioma, melanoma, myeloma, ovarian cancer, endometrial cancer, prostate cancer, pancreatic cancer, renal cell carcinoma, non-small cell lung cancer, small cell lung cancer, brain tumor, sarcoma, neuroblastoma, or squamous cell carcinoma of the head and neck.

[0150] In some embodiments, the methods disclosed herein can be used for the treatment or prevention of autoimmune diseases in subjects. In certain embodiments, autoimmune diseases include multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, celiac disease, Graves' disease, Hashimoto's autoimmune thyroiditis, vitiligo, rheumatic fever, pernicious anemia / atrophic gastritis, alopecia areata, immune thrombocytopenic purpura, temporal arteritis, ulcerative colitis, Crohn's disease, scleroderma, antiphospholipid syndrome, autoimmune hepatitis type 1, primary biliary cirrhosis, and sphygmomanitis. Glenn's syndrome, Addison's disease, herpetiform dermatitis, Kawasaki disease, sympathetic ophthalmitis, HLA-B27-associated acute anterior uveitis, primary sclerosing cholangitis, discoid lupus erythematosus, polyarteritis nodosa, CREST syndrome, myasthenia gravis, polymyositis / dermatomyositis, Still's disease, autoimmune hepatitis type 2, Wegener's granulomatosis, mixed connective tissue disease, microscopic polyangiitis, autoimmune polyglandular syndrome, Felty's syndrome, autoimmune Hemolytic anemia, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Behçet's disease, autoimmune neutropenia, bullous pemphigoid, essential mixed cryoglobulinemia, linear morphea, autoimmune polyglandular syndrome 1 (APECED), acquired hemophilia A, Batten disease / neuroceroid lipofuscinosis, autoimmune pancreatitis, Hashimoto's encephalopathy, Goodpasture disease, pemphigus vulgaris, autoimmune disseminated encephalomyelitis, recurrent The following conditions are selected from the group consisting of: polychondritis, Takayasu's arteritis, Churg-Strauss syndrome, acquired epidermolysis bullosa, pemphigoid scarring, pemphigus phyllodes, autoimmune hypoparathyroidism, autoimmune hypophysitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune oophoritis, autoimmune orchitis, autoimmune polyglandular syndrome, Cogan syndrome, encephalitis lethargica, erythema diphylaxis, Evans syndrome, immunomodulatory polyendocrine disorder, X-linked intestinal disease (IPEX), Isaacs syndrome / acquired neuromuscular totonia, Miller-Fischer syndrome, Moban syndrome, Pandas syndrome, Poems syndrome, Rasmussen encephalitis, Stiffperson syndrome, Vogt-Koyanagi-Harada syndrome, neuromyelitis optica, graft-versus-host disease, and autoimmune uveitis.

[0151] In some embodiments, cells are obtained from a subject, their genomes are edited to express exogenous and endogenous genes, and they are grown ex vivo before being administered to the subject for the treatment or prevention of disease. For example, in some embodiments, tumor-infiltrating lymphocytes, a heterogeneous and cancer-specific population of T cells, are obtained from a cancer subject and grown ex vivo. In certain embodiments, the characteristics of the cancer of the subject determine a set of tuned cell modifications (e.g., exogenous genes inserted into the cells), and these modifications are applied to tumor-infiltrating lymphocytes using any of the methods described herein.

[0152] The above description illustrates several aspects and embodiments of the present invention. This patent application explicitly intends to describe all combinations and permutations of aspects and embodiments. [Examples]

[0153] The present invention, as generally described herein, will be more readily understood by referring to the following examples, which are included solely for illustrative purposes of specific aspects and embodiments of the invention and are not intended to limit the invention.

[0154] Example 1 - Insertion of a CAR-transformed gene into TRAC This specification describes a non-viral genome editing method for inserting an exogenous transgene (e.g., encoding a CAR) into a target site within the TRAC gene of T cells. Cells into which the exogenous transgene and a sequence having equivalent coding ability to the 3' portion of TRAC have been successfully inserted express both the exogenously introduced CAR and a functional TCR complex, restoring or continuing TCRα chain expression.

[0155] T cell isolation and activation T cells were enriched from peripheral blood mononuclear cells (PBMCs) prepared using Lymphoprep (STEMCELL Technologies) from normal donor Leukopaks (STEMCELL Technologies) using the EasySep Human T-Cell Isolation Kit (STEMCELL Technologies). Subsequently, the T cells were activated in T-Cell TransAct, human (Miltenyi, 130-111-160) in TexMACS medium (Miltenyi, 130-197-196) supplemented with 3% human AB serum (Gemini Bio) and 12.5 ng / ml human IL-7 and IL-15 (Miltenyi, premium grade), and grown for 48 hours at 37°C and 5% CO2 before electroporation.

[0156] T-cell gene editing CRISPR RNPs were prepared by combining 120 μM of sgRNA (Synthego) target DNA sequence AAGTCTCTCAGCTGGTACA (SEQ ID NO: 1), 62.5 μM of sNLS-SpCas9-sNLS (Aldevron), 100 ng / ml of poly-L-glutamic acid (Sigma P4761-25MG), and P3 buffer (Lonza) in a ratio of 5:1:3:6. 5 μg of plasmid DNA (i.e., a plasmid with a sequence following SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13) was mixed with 17.5 μl of RNP. T cells were counted and centrifuged at 90 × G for 10 minutes, resulting in 5 × 10⁶ cells. 6Cells were resuspended in 94 μl of P3 with the additive (Lonza). The 94 μl T cell suspension was added to the DNA / RNP mixture, transferred to a Lonza electroporated cuvette, and pulsed with a Lonza X unit code EH-115. After allowing the cells to stand at room temperature for 10 minutes, they were transferred to 24-well G-Rex plates (Wilson Worf) in TexMACS medium supplemented with 12.5 ng / ml human IL-7 and IL-15 (Miltenyi, premium grade). Under some conditions, cells were harvested by mixing CTS Dynabeads (CD3 / CD28) (Thermo Fisher) in a 1:1 ratio with the aforementioned medium composition.

[0157] Flow cytometry Transgene expression was detected by staining with anti-EGFR antibody (BioLegend, clone AY13) and analyzed using an Attune NxT flow cytometer. TCR alpha / beta complex expression was detected with CD3E antibody (BD, clone UCHT1) and TCR alpha / beta antibody (BioLegend, clone IP26).

[0158] Genome editing of T cells to express CAR and TCRα chains T cells were genome-edited using a plasmid repair template via electroporation of CRISPR RNPs targeting the TRAC locus, expressing an exogenous transgene encoding CD19-4-1BB-CD3ξ-CAR 2A bound to a cleaved EGFR surface marker gene. As shown in Figure 3A, the specific targeted cleavage site at the TRAC locus interfered with the coding sequence of TRAC, resulting in electroporation of cells with a plasmid containing a sequence according to SEQ ID NO: 11, failure to express TCRα chain protein, and expression of the exogenous CAR transgene was demonstrated by the loss of TCR complex surface expression, as indicated by the absence of CD3ε and TCRα / β detection by flow cytometry (data not shown). Figures 3A and 3B show that the exogenous transgene was readily detectable in electroporated cells stained with EGFR antibody and analyzed by flow cytometry. As shown in Figures 3B and 3C, cells are electroporated with a plasmid containing a sequence following Sequence ID No. 12, and the plasmid repair template contains the 3' coding sequence following the CRISPR target cleavage site in TRAC and the 2A sequence. Co-translation of the CAR and EGFR transgene yields a TRAC locus containing the transgene in addition to the complete TCRα chain coding sequence. These cells express a detectable TCR complex on the cell surface, as indicated by the presence of CD3 (Figure 3B) and TCRα / β (Figure 3C). As shown in Figure 4, T cells electroporated with a plasmid containing the 3' coding sequence following the CRISPR target cleavage site in TRAC (i.e., plasmids containing sequences following Sequence ID No. 12 and No. 13) express the TCR complex and show greater responsiveness to TCR stimulation by CD3 / CD28 Dynabeads compared to T cells electroporated with a plasmid lacking the 3' coding sequence following the CRISPR target cleavage site in TRAC (i.e., plasmids containing a sequence following Sequence ID No. 11).

[0159] Example 2 - Insertion of a CAR-transformed gene into IL2RG This specification describes a non-viral genome editing method for inserting an exogenous gene circuit (e.g., encoding a CAR) into a target site within the IL2RG gene of T cells. Cells into which the exogenous transgene and a sequence having equivalent coding ability to the 3' portion of IL2RG have been successfully inserted express both the exogenously introduced CAR and a functional IL2RG complex, restoring or maintaining the expression of the IL-2 receptor γ chain.

[0160] T cell isolation and activation T cell enrichment from PMBCs and activation by T cell transacting were performed as described in Example 1.

[0161] Editing of T cell genes CRISPR RNPs were prepared by combining 36 μM of sgRNA (Synthego) target DNA sequence GTGTGTATTTCTGGCTGGAA (SEQ ID NO: 32) and 62.5 μM of sNLS-SpCas9-sNLS (Aldevron) in a ratio of 16.5:1. 0.25 μg of plasmid DNA (i.e., a plasmid with a sequence following SEQ ID NO: 33) was mixed with 3.5 μl of RNPs. T cells were counted and centrifuged at 90 × G for 10 minutes, resulting in 1 × 10⁶ cells. 6 Cells were resuspended in 14.5 μl of P3 with the additive (Lonza). 20 μl of T cell suspension was added to the DNA / RNP mixture and transferred to a Lonza 384-well electroporation plate, which was pulsed with Lonza HT code EH-115AA. After standing the cells at room temperature for 15 minutes, they were transferred to a 96-well plate (Sarstedt) in TexMACS medium supplemented with 12.5 ng / ml human IL-7 and IL-15 (Miltenyi, premium grade).

[0162] Flow cytometry Transgene expression was detected by staining with anti-Myc antibody (Cell Signaling Technology, clone 9B11) and analyzing the results using an Intellicyt iQue3 instrument. IL2RG expression was detected with CD132 antibody (Biolegend, clone TUGh4).

[0163] Genome editing of T cells to express the circuit and IL2RG chain T cells were genome-edited using a plasmid repair template via electroporation of CRISPR RNPs targeting the IL2RG locus, expressing an exogenous transgene encoding a circuit with Prime and CAR receptors and a Myc tag. Figure 5 shows that the exogenous transgene (Myc-tagged Prime receptor) is readily detectable in electroporated cells stained with an anti-Myc antibody and analyzed by flow cytometry. As shown in Figure 5, cells were electroporated with a plasmid having a sequence according to SEQ ID NO: 33, and the plasmid repair template, containing the 3' coding sequence following the CRISPR target cleavage site in IL2RG, along with the Prime and CAR receptors including the circuit, yields an IL2RG locus expressing the full-length IL-2 receptor γ chain coding sequence in addition to the transgene. These cells express a detectable IL2RG complex on the cell surface, as indicated by the presence of CD132 (Figure 5). As shown in Figure 6A, cells from four donors, electroporated with ps6651, IL2RG sgRNA, and CAS9 and assayed via flow cytometry, showed an increased proportion of cells expressing both IL2RG and the exogenous transgene from day 9 to day 14 post-electroporation. Furthermore, as shown in Figure 6B, cell populations in which the IL2RG gene was knocked out and the transgene was not incorporated showed depletion over time due to the lack of IL2RG expression.

[0164] Example 3 In vivo treatment of solid tumors in xenograft mouse models T cells expressing tumor antigen-specific CARs are produced by the genome editing methods described herein. Primary human solid tumor cells are grown in immunocompromised mice. Examples of solid cancer cells include solid tumor cell lines provided in The Cancer Genome Atlas (TCGA) and / or the Broad Cancer Cell Line Encyclopedia (CCLE, see Barretina et al., Nature 483:603 (2012)). Examples of solid cancer cells include primary tumor cells isolated from lung cancer, ovarian cancer, melanoma, colon cancer, gastric cancer, renal cell carcinoma, esophageal cancer, glioma, urothelial carcinoma, retinoblastoma, breast cancer, non-Hodgkin lymphoma, pancreatic cancer, Hodgkin lymphoma, myeloma, hepatocellular carcinoma, leukemia, cervical cancer, cholangiocarcinoma, oral cancer, head and neck cancer, or mesothelioma. These mice are used to test the efficacy of T cells expressing exogenous CAR transgenes and functional TCR complexes in a human tumor xenograft model. 1 x 10 5 ~1 × 10 7 After subcutaneous transplantation or injection of individual tumor cells, the tumor was reduced to 200-500 mm before the start of treatment. 3 The tumors are allowed to grow to a certain size. Next, T cells that have been genome-edited to express an exogenous CAR transgene and a functional TCR complex are introduced into the mice. By caliper measurement of tumor size or by tracking the intensity of the luciferase protein (ffluc) signal emitted by tumor cells expressing ffluc, it is possible to assess whether the tumor has shrunk in response to treatment with T cells that have been genome-edited to express an exogenous CAR transgene and a functional TCR complex.

[0165] Reference All disclosures in each of the patent documents and scientific papers referenced herein are invoked by reference for any purpose.

[0166] Equal portions The present invention can be embodied in other specific forms without departing from its spirit or essential features. Accordingly, the embodiments described herein should be considered illustrative in all respects and not limiting the invention as described herein. The scope of the invention is thus indicated not by the foregoing description but by the appended claims, and all modifications that fall within the meaning and scope of the claims are intended to be included therein.

Claims

1. 1. A composition for targeted insertion of a nucleic acid comprising a sequence having coding capacity equivalent to the 3′ and / or 5′ portions of an endogenous gene of a cell and an exogenous transgene, comprising: a guide RNA (gRNA) targeting the endogenous gene; an RNA-guided nuclease that forms a complex with the gRNA; and a nucleic acid comprising a sequence that forms a complex with said RNA-guided nuclease and that encodes one or more regions of homology with said endogenous gene, said sequence having coding capacity equivalent to the 3' and / or 5' portions of said endogenous gene, and said transgene. Including, the RNA-guided nuclease specifically cleaves the endogenous gene in the cell to create an insertion site, and a sequence of the nucleic acid having coding capacity equivalent to the 3' and / or 5' portion of the endogenous gene and the transgene are inserted into the insertion site, and the insertion of the sequence of the nucleic acid having coding capacity equivalent to the 3' and / or 5' portion of the endogenous gene and the transgene results in restoration or continuation of expression of the endogenous gene and expression of the transgene in the cell. The composition.

2. 2. The composition of claim 1, wherein the endogenous gene is selected from the group consisting of T cell receptor alpha chain constant region (TRAC), T cell receptor beta chain constant region (TRBC), CD3 gamma chain, CD3 delta chain, CD3 epsilon chain, CD3 zeta chain, IL-2R alpha chain, IL-2R beta chain, and IL-2R gamma chain (IL2RG).

3. The endogenous genes include beta actin (Actb), ATP synthase H+ transport, mitochondrial F0 complex subunit B1 (Atp5f1), beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphoribosyltransferase (Hprt), phosphoglycerate kinase I (Pgk1), peptidyl prolyl isomerase A (Ppia), ribo 2. The composition of claim 1, comprising a gene selected from the group consisting of somal protein S18 (Rps18), TATA box binding protein (Tbp), transferrin receptor (Tfrc), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase-activating protein zeta polypeptide (Ywhaz), Nanog homeobox (Nanog), zinc finger protein 42 (Rex1), and POU domain class 5 transcription factor 1 (Oct4).

4. The composition of any one of claims 1 to 3, wherein the transgene comprises a sequence encoding a chimeric antigen receptor (CAR).

5. The composition of any one of claims 1 to 4, wherein the cell is an immune cell, optionally a T cell, a CD4+ T cell, or a CD8+ T cell.

6. 6. The composition of any one of claims 1 to 5, wherein the RNA-guided nuclease is Cas9, and optionally the gRNA is a single guide RNA (sgRNA) or a crRNA:trans-activating RNA (tracrRNA).

7. A cell comprising a nucleic acid, (i) the nucleic acid comprises, from 5' to 3', (1) a sequence encoding the 5' portion of an endogenous gene of the cell; (2) a sequence having coding capacity equivalent to the 3' portion of the endogenous gene of the cell; (3) a sequence encoding an exogenous transgene; and (4) a sequence encoding the 3' portion of the endogenous gene of the cell; wherein the cells comprise (a) the endogenous gene encoded by (1) and (2); and (b) the transgene encoded by (3) or (ii) the nucleic acid comprises, from 5' to 3', (1) a sequence encoding the 5' portion of an endogenous gene of the cell; (2) a sequence encoding an exogenous transgene; (3) a sequence having coding capacity equivalent to the 5' portion of the endogenous gene of the cell; and (4) a sequence encoding the 3' portion of the endogenous gene of the cell; wherein the cells comprise (a) the transgene encoded by (2), and (b) the endogenous gene encoded by (3) and (4); Each of the following is expressed: The cells.

8. 8. The cell of claim 7, wherein the endogenous gene is selected from the group consisting of T cell receptor alpha chain constant region (TRAC), T cell receptor beta chain constant region (TRBC), CD3 gamma chain, CD3 delta chain, CD3 epsilon chain, CD3 zeta chain, IL-2R alpha chain, IL-2R beta chain, and IL-2R gamma chain (IL2RG).

9. The endogenous genes include beta actin (Actb), ATP synthase H+ transport, mitochondrial F0 complex subunit B1 (Atp5f1), beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphoribosyltransferase (Hprt), phosphoglycerate kinase I (Pgk1), peptidyl prolyl isomerase A (Ppia), ribosomal protein kinase A (RIK), ribosomal protein kinase B (RIK), ribosomal protein kinase B (RIK), ribosomal protein kinase C (RIK), ribosomal protein kinase D (RIK), ribosomal protein kinase E (RIK), ribosomal protein kinase F ...

8. The cell of claim 7, comprising a gene selected from the group consisting of ribosomal protein S18 (Rps18), TATA box-binding protein (Tbp), transferrin receptor (Tfrc), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase-activating protein zeta polypeptide (Ywhaz), Nanog homeobox (Nanog), zinc finger protein 42 (Rex1), and POU domain class 5 transcription factor 1 (Oct4).

10. The cell according to any one of claims 7 to 9, wherein the transgene comprises a chimeric antigen receptor (CAR).

11. The cell of any one of claims 7 to 10, wherein the cell is an immune cell, optionally a T cell, a CD4+ T cell, or a CD8+ T cell.

12. 1. A method for editing the genome of a cell, comprising: a guide RNA (gRNA) targeting an endogenous gene in the cell; an RNA-guided nuclease that forms a complex with the gRNA; and A nucleic acid comprising a sequence that forms a complex with said RNA-guided nuclease and that encodes one or more regions of homology with said endogenous gene, a sequence that has coding capacity equivalent to the 3' and / or 5' portions of said endogenous gene, and an exogenous transgene. into said cell, the RNA-guided nuclease specifically cleaves the endogenous gene in the cell to create an insertion site, and the nucleic acid sequence having coding capacity equivalent to the 3' and / or 5' portion of the endogenous gene and the exogenous transgene are inserted into the insertion site, and insertion of the nucleic acid sequence having coding capacity equivalent to the 3' and / or 5' portion of the endogenous gene and the exogenous transgene results in restoration or continuation of expression of the endogenous gene and expression of the transgene in the cell. The method.

13. 13. The method of claim 12, wherein the endogenous gene is selected from the group consisting of T cell receptor alpha chain constant region (TRAC), T cell receptor beta chain constant region (TRBC), CD3 gamma chain, CD3 delta chain, CD3 epsilon chain, CD3 zeta chain, IL-2R alpha chain, IL-2R beta chain, and IL-2R gamma chain (IL2RG).

14. The endogenous genes include beta actin (Actb), ATP synthase H+ transport, mitochondrial F0 complex subunit B1 (Atp5f1), beta-2 microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphoribosyltransferase (Hprt), phosphoglycerate kinase I (Pgk1), peptidyl prolyl isomerase A (Ppia), , ribosomal protein S18 (Rps18), TATA box binding protein (Tbp), transferrin receptor (Tfrc), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase-activating protein zeta polypeptide (Ywhaz), Nanog homeobox (Nanog), zinc finger protein 42 (Rex1), and POU domain class 5 transcription factor 1 (Oct4).

15. The method of any one of claims 12 to 14, wherein the transgene comprises a chimeric antigen receptor (CAR).

16. The method of any one of claims 12 to 15, wherein the cell is an immune cell, optionally a T cell, a CD4+ T cell, or a CD8+ T cell.

17. 17. The method of any one of claims 12 to 16, wherein the RNA-guided nuclease is Cas9, and optionally the gRNA is a single guide RNA (sgRNA) or a crRNA:trans-activating crRNA (tracrRNA).

18. 18. The method of any one of claims 12 to 17, wherein the introduction into the cell is non-viral, optionally wherein the non-viral introduction into the cell is via electroporation.

19. A pharmaceutical composition for treating or preventing a disease in a subject, comprising a cell according to any one of claims 7 to 11.